

INDEX TO VOLUME 23

AUTHOR INDEX

- Abdel-Rahman, H.A., 487
 Adatia, A., 241
 Aedo, A.-R., 107, 407
 Ahluwalia, B. S., 643
 Akerlund, M., 447
 Akpoviroro, J., 487
 Al-Amood, W. S., 543
 Alder, E., 45
 Al-Khateeb, E., 543
 Andino, N., 141
 Ansari, A. H., 507
 Assandri, A., 163
 Astedt, B., 435
 Back, D. J., 125, 229
 Bamji, M. S., 23
 Bancroft, J., 45
 Bates, M., 229
 Batra, S., 447
 Bernstein, G. S., 527
 Bhatt, R. V., 603
 Boonsiri, B., 301
 Breckenridge, A. M., 125, 229
 Brenner, P. F., 487
 Breuer, H., 1
 Briggs, Maxine, 463
 Briggs, Michael, 463
 Campbell, E. E., 181
 Casslén, B., 425, 435
 Castracane, V. D., 335
 Chakrabarty, S., 315
 Chan, T., 487
 Chapman, C. R., 125
 Chatterjee, A., 543
 Chatterjee (Basu), R., 543
 Chauhan, L. N., 603
 Chi, I.-C., 579
 Chumnijarakij, T., 517
 Cook, A., 45
 Cordell, G. A., 653
 Cortesi, S., 629
 Coutinho, E. M., 487
 Cox, C., 457
 Crawford, F. E., 125
 Croxatto, H. B., 197
 Curry, C. L., 643
 Debavalya, N., 517
 de Souza, J. C., 487
 Dey, S. K., 457
 Diaz, S., 197
 Diczfalusy, E., 107, 269, 407

CONTRACEPTION

- DiRaddo, J., 345
 Donde, U. M., 241
 Dozier, T. S., 487
 Dreyer, N. A., 181
 Dusitsin, N., 301
 Düsterberg, B., 77
 Elamsson, K., 197
 Ericson, E. W., 133
 Fan, H.-M., 591
 Farooq, A., 261
 Feldblum, P. J., 579
 Findley, W. E., 157
 Fioretti, P., 77
 Fong, H. H. S., 653
 Fotherby, K., 487
 Fruzzetti, F., 77
 Galliani, G., 163, 325
 Gallico, L., 163
 Gayathri, T. L., 11
 Glasser, M., 367
 Goldzieher, J. W., 335, 487
 Gomez-Rogers, C., 487
 Gopalan, S., 487
 Gould, K. G., 507
 Gray, J., 45
 Grech, E. S., 487
 Grossman, R. A., 517
 Gu, Z., 667
 Gual, C., 487
 Gumbinger, H. G., 661
 Hägstrom, B., 387
 Hahn, D. W., 133
 Hall, J. M., 229
 Hamberger, L., 387
 Han, L.-H., 591
 Hardt, W., 187
 Helm, G., 447
 Hickey, M. V., 487
 Hingorani, V., 211
 Jackson, M., 457
 Jain, A. K., 211
 Jantaraniyom, K., 55
 Jariwala, K., 603
 Jha, P., 211
 Ji, G., 591
 Johansson, E., 63
 Johansson, E. D. B., 197
 Joshi, U. M., 241
 Kabir, S. N., 677
 Kaul, L., 643
 Kemper, F. H., 661
 Kim, S. W., 487
 Klinger, H. P., 367
 Koetsawang, S., 487
 Konoseripong, R., 301
 Kumar, D., 211, 261
 Kurunmäki, H., 473
 Kwon, E., 487
 Lager, S., 269
 Lähteenmäki, Pekka, 63

CONTRACEPTION

- Lähteenmäki, Pertti, 63, 473
 Lai, M. T., 133
 Lancini, G., 163
 Landgren, B.-M., 107, 269, 407, 487
 Larsson, B., 387
 Laumas, K. R., 211, 261
 Laumas, V., 211
 Lewis, J. G., 181
 Lichtenberg, R., 487
 London, J., 45
 London, N. B., 45
 Luukkainen, T., 63, 473
 Luzzani, F., 163, 325
 Ma, L.-Y., 591
 MacIver, M., 229
 Madhavapeddi, R., 11
 Malik, B.K., 211
 Manabe, A., 621
 Manabe, Y., 621
 Mapa, M. K., 487
 Mehta, S., 241
 Melis, G. B., 77
 Miranda, P., 197
 Molina, R., 487
 Mukerjee, S., 457
 Nair, K. M., 89, 497, 549, 563
 Nevinny-Stickel, J., 187
 Nieschlag, E., 1
 Nukulkarn, P., 487
 Ohlsson, K., 425
 Oldani, C., 163
 Olsen, K. A., 125
 Omodei-Sale, A., 163
 Onthuam, Y., 517
 Orme, M. L'E., 125, 229
 Pachauri, S., 603
 Page, E. W., 37
 Pakrashi, A., 315, 677
 Paoletti, A. M., 77
 Park, B. K., 229
 Philips, F. S., 11
 Pizzo, S. V., 181
 Plunkett, E. R., 487
 Prasad, K. V. S., 99, 497, 563
 Prema, K., 11, 23, 497
 Probst, A., 133
 Rahman, S. A., 211
 Rainer, E., 77
 Ramalakshmi, B. A., 11
 Rao, B. S. N., 89, 99, 497, 549, 563
 Ratnam, S. S., 487
 Ray, H., 677
 Rigoni, G., 629
 Rowe, Ph. H., 125, 229
 Safaya, S., 23
 Sankolli, G. M., 241
 Sarkar, N. N., 211
 Saxena, B. N., 241
 Schmidt-Gollwitzer, M., 187
 Schreurs, W. H. P., 399

CONTRACEPTION

- Schwallie, P. C., 375
Shearman, R. P., 487
Sheth, U. K., 487
Sivakumar, B., 89, 99, 497, 549, 563
Snidvongs, W., 55
Soejarto, D. D., 653
Soffientine, A., 163
Sourgens, H., 661
Sposetti, R., 629
Sribyatta, B., 55
Strigini, F., 77
Takkar, D., 211
Tankeyoon, M., 301
Thorell, J., 435
Toivonen, J., 473
Toppozada, H. K., 487
Trifunac, N. P., 527
Tyrer, G., 45
van den Berg, H., 399
van Rijn, H. J. M., 399
Vathanasiritham, P., 55
Viberg, L., 387
Virutamasen, P., 301
von der Ohe, M., 187
Waller, D. P., 653
Wardell, W. M., 345
Warner, P., 45
Weiner, E., 63
Werawatgoompa, S., 301
Wickings, E. J., 1
Winterhoff, H., 661
Wu, J. T., 667
Wylde, R., 661
Zen, F., 629
Zeng, S., 591

INDEX TO VOLUME 23

SUBJECT INDEX

- Abortion,
 - mid-pregnancy, 621
 - rivanol-catheter supplemented with PGF_{2α} or quinine hydrochloride, 621
- Acceptance of family planning services, associated factors, 517
- Accidental pregnancies, use of Cu-7 IUD, 387
- Acid phosphatase activity in prostate, effect of p-coumaric acid (rat), 677
- Adrenal and ovarian steroids at different phases of menstrual cycle, 107, 407
- Aldosterone, level in hypertensive oral contraceptive users, 643
- Androstenedione, circadian variation during menstrual cycle, 407
- Anthropometric indices, relationship to plasma norethindrone levels, 497
- Antifertility activity,
 - DL 111-IT (mouse, rat, hamster), 163
 - 5α-stigmastane-3β, 5, 6β-triol-3-monobenzoate (mouse, rabbit), 315
 - zoapatle plant, 133
- Antigonadotropic activity,
 - formation of compounds from inactive phenolic precursors (rat), 661
 - lithosperm, 157
- Biological profile, 5 -stigmastane-3 , 5, 6 -triol-3-monobenzoate (mouse, rabbit), 315
- Blastocyst survival, effect of concanavalin A (mouse), 667
- Bleeding pattern,
 - effect of levonorgestrel-releasing intracervical contraceptive device, 473
 - effect of norethindrone acetate, 211
 - effect of norethisterone, 269
- Blood coagulation, effect of low-estrogen oral contraceptives, 463
- Body weight, effect of sterilization, 603
- Breast-fed newborns, plasma level of norethisterone enanthate, 77
- Brocresine (4-Bromo-3-hydroxybenzylamine dihydrogen phosphate),
 - effect on implantation (mouse), 457
- Buserelin (D-Ser(TBU)⁶-EA¹⁰-LH-RH),
 - effect on bleeding pattern, 187
 - effect on estradiol secretion, 187
 - effect on FSH levels, 187

CONTRACEPTION

- effect on LH levels, 187
- effect on progesterone secretion, 187
- influence on cyclic ovarian function, 187
- influence on endometrium, 187
- LH-RH analogue, 187
- side effects, 187
- Caffeine, level in hypertensive oral contraceptive users, 643
- Carbohydrate metabolism, effect of norethisterone enanthate and norethisterone acetate, 141
- Cervical dilatation, use of 15-methyl-PGF_{2 α} methyl ester vaginal suppository, 251
- Cervical mucus, electrolyte composition during menstrual cycle, 507
- Cervical mucus changes during menstrual cycle, correlation with plasma gonadotrophins and ovarian steroids pattern, 629
- Cervix, effect of estradiol + d-norgestrel contraceptive vaginal ring, 241
- Chemical methods, male fertility control, 1
- Chinese priority programme for male fertility control, 1
- Chinese women, menstrual blood loss, 591
- 6-Chloro-6-deoxyglucose, male fertility control, 1
- Circadian variation, steroid and lutropin levels at different phases of menstrual cycle, 407
- Clinical effects, norethisterone enanthate, 77
- Clinical experience, long-term Cu-7 IUD use, 387
- Clinical investigational activity of U.S. pharmaceutical industry, contraceptives, 345
- Clinical investigational activity outside U.S. pharmaceutical industry, contraceptives, 345
- Clinical performance, estradiol + d-norgestrel contraceptive vaginal ring, 241
- Clinical requirements for contraceptive drugs, 345
- Clinical trial,
 - norethisterone enanthate, 11
 - norethisterone enanthate and norethisterone acetate, 141
- Coagulating gland fructose content, effect of *p*-coumaric acid (rat), 677
- Comparison of pharmacokinetics of levonorgestrel in women and rabbits, 89
- Comparison of sterilised women with wives of vasectomized men, effects of sterilisation, 45
- Complaints, following sterilization, 603

CONTRACEPTION

- Compounds with antigonadotropic activity, formation from inactive phenolic precursors (rat), 661
- Concanavalin A,
 - effect of intrauterine injection on implantation (mouse, rat), 667
 - effect on blastocyst survival (mouse), 667
 - effect on pregnancy (mouse), 667
 - induction of deciduomata (mouse), 667
- Conception rate, effect of STS-557 (baboon), 335
- Conceptus and contraceptives, 367
- Conceptus weight, effect of DL 111-IT (rat, hamster), 163
- Contraceptive new chemical entities marketed in U.S. and Great Britain, 345
- Contraceptive vaginal ring, estradiol + d-norgestrel, 241
- Contraceptives,
 - clinical investigational activity of U.S. pharmaceutical industry, 345
 - new chemical entities marketed in U.S., 345
 - U.S. clinical investigational activity outside pharmaceutical industry, 345
- Contraceptives and conceptus, 367
- Correlation of plasma gonadotrophins and ovarian steroids pattern with symptomatic changes in cervical mucus during menstrual cycle, 629
- Correlations between electrolytes and hormones in cervical mucus, 507
- Cortisol levels,
 - circadian variation during menstrual cycle, 407
 - normal menstrual cycle, 301
 - perioviulatory period, 107
- p-Coumaric acid (3-(4-hydroxy phenyl)-2-propenoic acid),
 - effect on acid phosphatase, activity in prostate (rat), 677
 - effect on fructose content of coagulating gland (rat), 677
 - effect on mating rate (rat), 677
 - effect on testosterone level (rat), 677
 - effect on weight of male reproductive organs (rat), 677
 - male reproductive inhibitor (rat), 677
- Cu-7, IUD,
 - accidental pregnancies, 387
 - expulsions, 387

CONTRACEPTION

- long-term clinical experience, 387
- pelvic inflammatory disease, 387
- removal for bleeding/pain, 387
- Cyclic variation, proteinase inhibitors in uterine fluid, 425
- Deciduogenicity of concanavalin A (mouse), 667
- Dehydroepiandrosterone, circadian variation during menstrual cycle, 407
- Deoxycorticosterone, level in hypertensive oral contraceptive users, 643
- Development of sexual characteristics, effect of medroxyprogesterone acetate given during lactation (rat), 375
- Different populations, pharmacokinetics of ethinyloestradiol, 487
- 20 α -Dihydroprogesterone levels,
 - characteristic in normal menstrual cycle, 269
 - effect of norethisterone, 269
- Dihydrotestosterone, circadian variation during menstrual cycle, 407
- Dilatation of cervix prior to vacuum aspiration, use of 15-methyl-PGF₂ α methyl ester, 251
- Diurnal variation, steroid and lutropin levels at different phases of menstrual cycles, 407
- DL 111-IT(3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole),
 - antifertility activity (mouse, rat, hamster), 163
 - effect on conceptus weight (rat, hamster), 163
 - effect on PGF₂ α metabolism in lung (hamster), 325
 - effect on PGF₂ α metabolism in utero-placental unit and lung (rat), 325
 - effect on plasma progesterone level (rat, hamster, dog), 163
 - effects on metabolism of PGF₂ α (rat, hamster), 325
 - mechanism of action (mouse, rat, hamster, dog), 163
 - mechanism of action (rat, hamster), 325
 - pregnancy termination activity (mouse, rat, hamster, dog), 163
- Drug development and pharmaceutical regulation in U.S., 345
- Dynamic changes during periovulatory period, ovarian and adrenal steroids, 107
- Early pregnancy, effect of zoaplatle plant (mouse, rat, hamster, guinea pig), 133
- Ectopic pregnancy, true sterilization failures, 579
- Electrolyte interaction in cervical mucus,
 - menstrual cycle, 507
 - relationship to circulating hormone levels, 507

- Endocrine effects, norethisterone enanthate, 77
- Endocrine profile, estradiol + d-norgestrel, 241
- Endometrium, influence of buserelin, 187
- Enzymatic cleavage of norethisterone oenanthate, 125
- Enzymes, effect of norethisterone enanthate, 23
- Epididymis, site for interference with fertility, 1
- Estradiol + d-norgestrel,
 - clinical performance of contraceptive vaginal ring, 241
 - contraceptive vaginal ring, 241
 - effect on menstrual pattern, 241
 - effect on metabolic parameters, 241
 - endocrine profile, 241
- Estradiol levels,
 - circadian variation during menstrual cycle, 407
 - effect of buserelin, 187
 - effect of estradiol + d-norgestrel, 241
 - effect of levonorgestrel-releasing intracervical contraceptive device, 473
 - effect of norethindrone acetate, 211
 - effect of norethisterone, 269
 - effect of ST-1435, 63
 - effect of STS-557 (baboon), 335
 - normal menstrual cycle, 301
 - perioovulatory phase, 107
 - relationship to electrolyte interaction in cervical mucus, 507
- Estradiol to estrone ratio, perioovulatory period, 107
- Estradiol-17 β and progesterone, comparison of plasma and myometrial tissue concentrations, 447
- Estrone,
 - effect on metabolism and motility of spermatozoa, 527
 - level during perioovulatory period, 107
- Ethinyl estradiol + levonorgestrel, effect on 25-hydroxycholecalciferol level, 399
- Ethynylestradiol,
 - level in hypertensive oral contraceptive users, 643
 - pharmacokinetics, 229, 487

CONTRACEPTION

- plasma levels after oral and intravenous administration of ethynylestradiol + levonorgestrel, 229
- Ethynylestradiol + ethynodiol diacetate, metabolic effects, 463
- Ethynylestradiol + levonorgestrel,
 - comparison of intravenous and oral administration, 229
 - metabolic effects, 463
- Ethynylestradiol + norethisterone, metabolic effects, 463
- Ethynylestradiol and levonorgestrel, pharmacokinetics, 229
- Ethynylestradiol levels, after oral ethynylestradiol, 487
- Experience with tampon-spermicide device, 37
- Expulsions, use of Cu-7 IUD, 387
- Factors associated with family planning acceptance, 517
- Family planning acceptance, associated factors, 517
- Family planning services,
 - acceptors' choice of contraception, 517
 - method and service factors, 517
 - socio-demographic and cultural characteristics, 517
 - source of contraceptive methods, 517
 - use in community survey, 517
- Fertility, after withdrawal of norethisterone enanthate, 11
- Fertility rate, effect of gossypol and its impurities (hamster), 653,
- Fetal metabolism, medroxyprogesterone acetate, 375
- Fetus,
 - effect of medroxyprogesterone acetate, 375
 - effect on sex after oral contraceptive use, 367
- Fibrinolytic activity,
 - radioassay, 181
 - uterine fluid, 435
- Fibrinolytic activity of uterine fluid, effect of IUD, 435
- Fibrinolytic factors, effect of low-estrogen oral contraceptives, 463
- Fibrinolytic response, oral contraceptive associated thromboembolism, 181
- Fluid-filled silastic capsule, norethisterone acetate, 261
- Follicle stimulating hormone (FSH)
- Follicular phase of menstrual cycle,
 - circadian variation in steroid and lutrophin levels, 407
 - plasma and myometrial tissue concentrations of estradiol-17 β and progesterone, 447

Follitropin (FSH)

Follow-up study of sterilized women, 603

Food restriction (undernutrition),

effect on liver drug metabolizing enzymes (rabbit), 563

effect on nutritional status, 563

effect on pharmacokinetics of levonorgestrel (rabbit), 549

effect on pharmacokinetics of norethindrone (rabbit), 99

effect of plasma sex hormone binding globulin capacity (rabbit), 563

effect on uterine cytosol progesterone receptor levels (rabbit), 563

Fructose content of coagulating gland, effect of p-coumaric acid (rat), 677

FSH (Follicle stimulating hormone or follitropin)

FSH levels,

effect of buserelin, 187

effect of norethindrone acetate, 211

effect of norethisterone, 269

effect of norethisterone enanthate, 77

effect of ST-1435, 63

normal menstrual cycle, 301

relationship to electrolyte interaction in cervical mucus, 507

Glucose tolerance test,

effect of low-estrogen oral contraceptives, 463

effect of norethisterone enanthate, 23

Gonadotrophins and ovarian steroids pattern, correlation with symptomatic changes

in cervical mucus during menstrual cycle, 629

Gossypol, male fertility control, 1

Gossypol and its impurities,

effect on fertility rate (hamster), 653

effect on sperm in vaginal smears (hamster), 653

effect on weight (male hamster), 653

male antifertility effects (hamster), 653

Gynecological pathology, effect of sterilization, 603

Gynecological surgery, subsequent to sterilization, 603

Hematological findings, relationship of menstrual blood loss, 591

Hematology, effect of norethisterone enanthate, 23

Histidine decarboxylase, effect of inhibition on implantation (mouse), 457

Hormonal changes in normal menstrual cycle, 301

CONTRACEPTION

- Hormonal estimations, menstrual cycle, 629
- Hormonal-symptomatic correlations, menstrual cycle, 629
- Hydrolysis by plasma of various species, norethisterone oenanthate, 125
- Hydrolysis by rabbit and human tissues, norethisterone oenanthate, 125
- Hydrolysis of norethisterone oenanthate, schematic representation, 125
- 25-Hydroxycholecalciferol levels,
 - effect of ethinyl estradiol + levonorgestrel, 399
 - effect of IUD, 399
 - effect of oral contraceptives, 399
- 3-(4-Hydroxy phenyl)-2-propenoic acid (p-coumaric acid),
- 17-Hydroxypregnenolone, circadian variation during menstrual cycle, 407
- 17-Hydroxyprogesterone levels,
 - characteristic in normal menstrual cycle, 269
 - circadian variation during menstrual cycle, 407
 - during periovulatory period, 107
 - effect of norethisterone, 269
- Hypertensive oral contraceptive users, levels of ethynylestradiol, caffeine,
 - aldosterone and deoxycorticosterone, 643
- Immunological approach, male fertility control, 1
- Implant contraceptive,
 - levonorgestrel, 197
 - norethindrone acetate, 211
 - ST-1435, 63
- Implantation,
 - effect of Brocresine (mouse), 457
 - effect of inhibition of histidine decarboxylase (mouse), 457
 - effect of intrauterine injection of concanavalin A (mouse, rat), 667
- Impurities of gossypol, effect on male fertility (hamster), 653
- Inhibin, male fertility control, 1
- Injectable contraceptive,
 - norethindrone enanthate, 497
 - norethisterone enanthate, 11, 23, 77, 141
- Insulin response, effect of low-estrogen oral contraceptives, 463
- Interval female sterilization, luteal phase pregnancies, 579
- Intracervical contraceptive device, levonorgestrel-releasing, 473
- Intranasal administration, buserelin, 187

Intrauterine device (IUD),

Cu-7, 387

effect of unilateral insertion (mouse, rat, rabbit), 543

effect on fibrinolytic activity of uterine fluid, 435

effect on 25-hydroxycholecalciferol level, 399

effect on plasminogen activators in uterine fluid, 435

effect on urokinase-like immunoreactivity in uterine fluid, 435

influence on proteinase inhibitors in uterine fluid, 425

levonorgestrel-releasing Nova-T, 473

TCu 200, 425, 435

IUD (intrauterine device)

Lactation, effect of norethisterone enanthate, 11

Lactational amenorrhea, effect of norethisterone enanthate, 11

Levonorgestrel,

comparison of pharmacokinetics in women and rabbits, 89

pharmacokinetics, 229

pharmacokinetics (rabbit), 89, 549

radioimmunoassay, 229

silastic capsule, 197

Levonorgestrel levels,

effect of food restriction (undernutrition) (rabbit), 549

levonorgestrel-releasing intracervical contraceptive device, 473

oral and intravenous administration of ethynylestradiol + levonorgestrel,
229

use of silastic capsules containing levonorgestrel, 197

Levonorgestrel-releasing intracervical contraceptive device,

effect on bleeding pattern, 473

effect on estradiol level, 473

effect on ovulation, 473

effect on progesterone level, 473

plasma levonorgestrel concentrations, 473

LH (Luteinizing hormone or lutropin)

LH levels,

circadian variation during menstrual cycle, 407

effect of buserelin, 187

effect of norethindrone acetate, 211

effect of norethisterone, 269

CONTRACEPTION

- effect of norethisterone enanthate, 77
- effect of ST-1435, 63
- normal menstrual cycle, 301
- perioviulatory period, 107
- relationship to electrolyte interaction in cervical mucus, 507
- LH-RH (Luteinizing hormone releasing hormone)
- LH-RH analogue,
 - male fertility control, 1
 - D-Ser(TBU)⁶-EA¹⁰-LH-RH (Buserelin), 187
- Limitations of male fertility control with steroids, 1
- Lipid metabolism, effect of norethisterone enanthate and norethisterone acetate, 141
- Lipids,
 - effect of low-estrogen oral contraceptives, 463
 - effect of norethisterone enanthate, 23
- Lithosperm (Lithospermum ruderale),
 - antigonadotropic activity, 157
 - inhibition of LRF-induced gonadotropin release in vitro, 157
- Liver drug metabolizing enzymes, effect of food restriction (undernutrition) (rabbit), 563
- Liver function, effect of norethisterone enanthate and norethisterone acetate, 141
- Long-term use of silastic capsules containing levonorgestrel, plasma levels of levonorgestrel, 197
- Low-estrogen oral contraceptives,
 - effect on blood coagulation, 463
 - effect on fasting plasma lipids, 463
 - effect on fibrinolytic factors, 463
 - effect on glucose tolerance tests, 463
 - effect on plasma insulin response, 463
 - metabolic effects, 463
- LRF (Lutropin releasing factor)
- LRF-induced gonadotropin release, inhibition by lithosperm, 157
- Luteal phase of menstrual cycle,
 - circadian variation in steroid and lutropin levels, 407
 - concentration of proteinase inhibitors in uterine fluid, 425

- plasma and myometrial tissue concentrations of estradiol-17 β and progesterone, 447
- Luteal phase pregnancy, sterilization patients, 579
- Luteinizing hormone (LH)
- Luteinizing hormone releasing hormone (LH-RH)
- Luteolytic effect, unilateral IUD (mouse, rat, rabbit), 543
- Lutropin (LH)
- Male antifertility effects, gossypol and its impurities (hamster), 653
- Male contraceptive pill, gossypol, 1
- Male fertility control,
 - chemical methods, 1
 - 6-chloro-6-deoxyglucose, 1
 - function of pineal gland, 1
 - gossypol, 1
 - immunological approach, 1
 - LH-RH analogue, 1
 - study of male infertility, 1
 - use of inhibin, 1
 - use of new steroids, 1
- Male fertility control with steroids, limitations and prospects, 1
- Male infertility, approach to fertility control, 1
- Male reproductive inhibitor, p-coumaric acid (rat), 677
- Maternal contraceptive histories, effect on sex distribution of subsequent conceptus, 367
- Mating rate,
 - effect of p-coumaric acid (rat) 677
 - effect of p-coumaric acid with testosterone and/or prolactin (rat) 677
- Measures of innovation in pharmaceuticals, 345
- Mechanism of action,
 - DL 111-IT (mouse, rat, hamster, dog), 163
 - DL 111-IT (rat, hamster), 325
- Medicated IUDs, research activity by U.S. pharmaceutical industry, 1963-1976, 345
- Medroxyprogesterone acetate,
 - effect on fetus and nursing infant, 375
 - effect on mental development after exposure in utero, 375
 - effect on sexual dimorphic behavior after exposure in utero, 375

CONTRACEPTION

- fetal metabolism, 375
- Medroxyprogesterone acetate given during lactation, effect on development of sexual characteristics (rat), 375
- Menstrual blood loss,
 - comparison between subjective judgment and quantitative determination, 591
 - effect of menstrual pattern, 591
 - healthy Chinese women, 591
 - relation to age, marital status and parity, 591
 - relationship to hematological findings, 591
- Menstrual cycle,
 - circadian variation in steroid and lutropin levels, 407
 - correlation of gonadotrophins and ovarian steroids pattern with symptomatic changes in cervical mucus, 629
 - cortisol concentration, 301
 - effect of norethisterone enanthate, 11
 - estradiol concentration, 301
 - estradiol-17 β and progesterone concentrations in plasma and myometrial tissue, 447
 - FSH concentration, 301
 - hormonal changes, 301
 - hormonal estimations, 629
 - LH concentration, 301
 - ovarian and adrenal steroid at different phases, 107
 - progesterone concentration, 301
 - prolactin concentration, 301
 - symptomatic mucus pattern, 629
 - testosterone concentration, 301
- Menstrual pattern,
 - after withdrawal of norethisterone enanthate, 11
 - effect of estradiol + d-norgestrel contraceptive vaginal ring, 241
 - effect of sterilization, 603
 - effect on menstrual blood loss, 591
- Mental development, effect of medroxyprogesterone acetate after exposure in utero, 375,
- Mestranol + norethindrone, oral contraceptive, 643
- Metabolic effects of low-estrogen oral contraceptives, 463

CONTRACEPTION

- Metabolic parameters, effect of estradiol + d-norgestrel contraceptive vaginal ring, 241
- Metabolism of $\text{PGF}_{2\alpha}$, effect of DL 111-IT (rat, hamster), 325
- Metabolism of spermatozoa, effect of steroid hormones, 527
- 15-Methyl- $\text{PGF}_{2\alpha}$ methyl ester, vaginal suppository for preoperative cervical dilatation, 251
- Mid-pregnancy abortion, rivanol-catheter supplemented with $\text{PGF}_{2\alpha}$ or quinine hydrochloride, 621
- Minerals, effect of norethisterone enanthate, 23
- Motility of spermatozoa, effect of steroid hormones, 527
- Myometrial tissue and plasma concentrations, estradiol-17 β and progesterone during menstrual cycle, 447
- Neonate, effect on sex after oral contraceptive use, 367
- New chemical entities marketed in U.S., contraceptives, 345
- Nonoxynol-9, use in tampon-spermicide device, 37
- Norethindrone, pharmacokinetics (rabbit), 99
- Norethindrone acetate,
 effect on bleeding pattern, 211
 effect on estradiol level, 211
 effect on FSH level, 211
 effect on LH level, 211
 effect on progesterone level, 211
 silastic capsule, 211
- Norethindrone enanthate,
 effect on progesterone levels, 497
 injectable contraceptive, 497
 plasma norethindrone levels, 497
- Norethindrone levels,
 effect of norethindrone acetate silastic implant, 211
 effect of norethindrone enanthate, 497
 relationship to anthropometric indices, 497
- Norethisterone,
 comparison of short-term and medium-term effects, 269
 effect on bleeding pattern, 269
 effect on ovarian response, 269
 effect on plasma level of 20 α -dihydroprogesterone, 269

CONTRACEPTION

- effect on plasma level of estradiol, 269
- effect on plasma level of 17-hydroxyprogesterone, 269
- effect on plasma level of immunoreactive hFSH, 269
- effect on plasma level of immunoreactive hLH, 269
- effect on plasma level of progesterone, 269
- oral contraceptive, 269
- plasma concentrations during use of norethisterone enanthate as injectable contraceptive, 77

Norethisterone acetate,

- clinical trial, 141
- effect on carbohydrate metabolism, 141
- effect on lipid metabolism, 141
- effect on liver function, 141
- effect on renal function, 141
- effect on thyroid function, 141
- fluid-filled silastic capsule, 261
- oral contraceptive, 141
- release rate from fluid-filled silastic capsule, 261

Norethisterone enanthate,

- clinical effects, 77
- clinical trial, 11, 141
- effect of vitamin supplement, 23
- effect on carbohydrate metabolism, 141
- effect on enzymes, 23
- effect on glucose tolerance test, 23
- effect on hematology, 23
- effect on indices of nutritional status, 11
- effect on lactation and lactational amenorrhea, 11
- effect on lipid metabolism, 141
- effect on liver function, 141
- effect on menstrual cycle, 11
- effect on minerals, 23
- effect on plasma lipids, 23
- effect on plasma vitamin A level, 23
- effect on proteins, 23
- effect on pyridoxine status, 23
- effect on renal function, 141

- effect on riboflavin status, 23
- effect on thyroid function, 141
- effect on urinary excretion of xanthurenic and kynurenic acid after tryptophan load, 23
- endocrine effects, 77
- in puerperal and non-puerperal women, 77
- injectable contraceptive, 11, 23, 77, 141
- menstrual pattern and fertility after withdrawal, 11
- metabolic side effects, 23
- norethisterone concentrations during use as injectable contraceptive, 77
- plasma level in breast-fed newborns, 77
- Norethisterone oenanthate (17 α -Ethinyl-17 β -hydroxy-oestr-4-en-3-one-17-heptanoate),
 - hydrolysis by plasma of various species, 125
 - hydrolysis by rabbit and human tissues, 125
 - studies on enzymatic cleavage, 125
- d-Norgestrel,
 - daily oral contraceptive, 55
 - effect on serum progesterone, 55
 - pattern of spotting and bleeding, 55
- d-Norgestrel levels, effect of estradiol + d-norgestrel, 241
- Nursing infant, effect of medroxyprogesterone acetate, 375
- Nutritional status,
 - effect of food restriction (undernutrition) (rabbit), 563
 - effect of norethisterone enanthate, 11
- Oral contraceptive,
 - associated thromboembolism and fibrinolytic response, 181
 - effect on sex of fetus and neonate, 367
 - ethynylestradiol + ethynoidiol diacetate, 463
 - ethynylestradiol + levonorgestrel, 463
 - ethynylestradiol + norethisterone, 463
 - mestranol + norethindrone, 643
 - norethisterone, 269
 - norethisterone acetate, 141
 - d-norgestrel, 55
- Oral contraceptive users, hypertension, 643

CONTRACEPTION

- Ovarian and adrenal steroids at different phases of menstrual cycle, 107, 407
- Ovarian function,
 effect of ST-1435, 63
 influence of buserelin, 187
- Ovarian response, effect of norethisterone, 269
- Ovarian steroids pattern and gonadotropions, correlation with symptomatic changes
 in cervical mucus during menstrual cycle, 629
- Ovulation effect of levonorgestrel-releasing intracervical contraceptive device,
 473
- Ovulation Method Billings, 629
- Ovulatory phase, plasma and myometrial tissue concentrations of estradiol-17 β
 and progesterone, 447
- Pattern of pregnancy arrest, DL 111-IT (rat, hamster), 163
- Pelvic inflammatory disease, use of CU-7 IUD, 387
- Perioviulatory cervical mucus, electrolyte composition, 507
- Perioviulatory phase of menstrual cycle,
 circadian variation in steroid and lutropin levels, 407
 study on ovarian and adrenal steroids, 107
- PG (Prostaglandin)
- PGF $_{2\alpha}$ metabolism, effect of DL 111-IT (rat, hamster), 325
- PGF $_{2\alpha}$ supplementation of rivanol-catheter method, mid-pregnancy abortion,
 621
- Pharmaceutical industry, research activity on systemic contraceptive drugs,
 1963-1976, 345
- Pharmacokinetic parameters, ethinyloestradiol, 487
- Pharmacokinetic parameters of levonorgestrel, comparison in women and rabbits,
 89
- Pharmacokinetics,
 ethinyloestradiol and levonorgestrel, 229
 ethinyloestradiol, 487
 levonorgestrel (rabbit), 89, 549
 norethindrone (rabbit), 99
- Pharmacokinetics of ethinyloestradiol in different populations, 487
- Pharmacokinetics of levonorgestrel, effect of food restriction (undernutrition)
 (rabbit), 549
- Pharmacokinetics of norethindrone, effect of food restriction (undernutrition)
 (rabbit), 99

CONTRACEPTION

- Phenolic precursors, formation of compounds with antigonadotropic activity (rat), 661
- Pineal gland, function in male fertility control, 1
- Pituitary function, effect of ST-1435, 63
- Plasma and myometrial tissue concentrations, estradiol-17 β and progesterone during menstrual cycle, 447
- Plasminogen activators, effect of IUD, 435
- Plasminogen activators in uterine fluid, 435
- Postcoital contraceptive, evaluation of STS-557 (baboon), 335
- Postmenopausal women, estradiol-17 β and progesterone concentrations in plasma and myometrial tissue, 447
- Preclinical requirements for contraceptive drugs, 345
- Pregnancy,
 - effect of intrauterine injection of concanavalin A (mouse, rat), 667,
 - effect of 5 α -stigmastane-3 β , 5, 6 β -triol-3-monobenzoate (mouse), 315
 - effect of unilateral IUD (mouse, rat, rabbit), 543
 - female sterilization patients, 579
 - true sterilization failures, 579
- Pregnancy rate, after sterilization, 603
- Pregnancy termination activity, DL 111-IT (mouse, rat, hamster, dog), 163
- Pregnenolone, circadian variation during menstrual cycle, 407
- Premenopausal women, estradiol-17 β and progesterone concentrations in plasma and myometrial tissue, 447
- Progesterone,
 - circadian variation during menstrual cycle, 407
 - effect on metabolism and motility of spermatozoa, 527
 - level during periovulatory period, 107
- 11- β -OH-Progesterone, effect on metabolism and motility of spermatozoa, 527
- Progesterone and estradiol-17 β , comparison of plasma and myometrial tissue concentrations, 447
- Progesterone levels,
 - effect of buserelin, 187
 - effect of daily d-norgestrel, 55
 - effect of DL 111-IT (rat, hamster, dog), 163
 - effect of estradiol + d-norgestrel, 241
 - effect of levonorgestrel-releasing intracervical contraceptive device, 473

CONTRACEPTION

- effect of norethindrone acetate, 211
- effect of norethindrone enanthate, 497
- effect of norethisterone, 269
- effect of ST-1435, 63
- effect of STS-557 (baboon), 335
- normal menstrual cycle, 301
- relationship to electrolyte interaction in cervical mucus, 507
- Prolactin and/or testosterone with p-coumaric acid, effect on mating rate and weight of male reproductive organs (rat), 677
- Prolactin levels,
 - effect of norethisterone enanthate, 77
 - normal menstrual cycle, 301
- Proliferative phase of menstrual cycle, concentration of proteinase inhibitors in uterine fluid, 425
- Prospects of male fertility control with steroids, 1
- Prostaglandin (PG),
 - 15-methyl-PGF_{2α} methyl ester, 251
- Prostate acid phosphatase activity, effect of p-coumaric acid (rat), 677
- Proteinase inhibitors,
 - cyclic variation in uterine fluid, 425
 - influence of IUD, 425
- Proteins, effect of norethisterone enanthate, 23
- Puerperal women, use of injectable norethisterone enanthate, 77
- Pyridoxine status, effect of norethisterone enanthate, 23
- Quantitative determination compared to subjective judgment, menstrual blood loss, 591
- Quinhydrone formation, compounds with antigonadotropic activity (rat), 661
- Quinine hydrochloride supplementation of rivanol-catheter method, mid-pregnancy abortion, 621
- Rabbit as animal model, use in pharmacokinetic study of levonorgestrel in women, 89
- Radioassay, fibrinolytic activity, 181
- Radioimmunoassay,
 - levonorgestrel, 229
 - ST-1435, 63
- Reaction involved in formation of effective antigonadotropic compounds, 661

CONTRACEPTION

- Regulatory developments governing new drugs, 345
- Release rate, norethisterone acetate from fluid-filled silastic capsules, 261
- Removal for bleeding/pain, use of CU-7 IUD, 387
- Renal function, effect of norethisterone enanthate and norethisterone acetate, 141
- Reproductive organ weights in male,
 effect of p-coumaric acid (rat), 677
 effect of p-coumaric acid with testosterone and/or prolactin (rat), 677
- Research activity on systemic contraceptive drugs by U.S. pharmaceutical industry, 1963-1976, 345
- Riboflavin status, effect of norethisterone enanthate, 23
- Rivanol-catheter method supplemented with PGF_{2 α} or quinine hydrochloride, mid-pregnancy abortion, 621
- Secondary sex organs, effect of 5 α -stigmastane-3 β , 5, 6 β -triol-3-monbenzoate (mouse), 315
- Sex distribution, effect of maternal contraceptive histories, 367
- Sex hormone binding globulin capacity, effect of food restriction (undernutrition) (rabbit), 563
- Sex of fetus and neonate, effect of oral contraceptive, 367
- Sexual dimorphic behavior, effect of medroxyprogesterone acetate after exposure in utero, 375
- Sperm in vaginal smears, effect of gossypol and its impurities (hamster), 653
- Spermatozoa,
 effect of steroid hormones on CO₂ production, 527
 effect of steroid hormones on lactic acid production, 527
 effect of steroid hormones on metabolism, 527
 effect of steroid hormones on motility, 527
 effect of steroid hormones on oxygen uptake, 527
 effect of steroid hormones on viability, 527
- Spermicide, nonoxynol-9, 37
- ST-1435 (16-Methylene-17 β -acetoxy-19-nor-4-pregnen-3,20-dione),
 effect on pituitary and ovarian function, 63
 plasma concentrations during use of subcutaneous capsules containing ST-1435, 63
 radioimmunoassay, 63
 subcutaneous capsule, 63

CONTRACEPTION

Sterilised women compared with wives of vasectomized men, effects of sterilisation, 45

Sterilization,

- effect on body weight, 603
- effect on gynecological pathology, 603
- effect on menstrual pattern, 603
- effect on sterilised women compared with wives of vasectomized men, 45
- effect on subsequent gynecological surgery, 603
- follow-up complaints, 603
- follow-up study of women, 603
- subsequent pregnancy rate, 603

Sterilization patients, luteal phase pregnancies, 579

Steroid hormones,

- effect on metabolism of spermatozoa, 527
- effect on motility of spermatozoa, 527
- effect on viability of spermatozoa, 527

5 α -Stigmastane-3 β , 5,6 β -triol-3-monobenzoate, antifertility activity (mouse, rabbit), 315
biological profile (mouse, rabbit), 315
effect on pregnancy (mouse), 315
effect on secondary sex organs (mouse), 315
effect on uterine weight (mouse) 315

STS-557 (17 α -Cyanomethyl-17 β -hydroxy-estra-4,9(10)-diene-3-one),
effect on conception rate (baboon), 335
effect on estradiol level (baboon), 335
effect on progesterone level (baboon), 335
evaluation as postcoital contraceptive (baboon), 335

Subcutaneous capsules, ST-1435, 63

Subjective judgment compared to quantitative determination, menstrual blood loss, 591

Symptomatic changes in cervical mucus during menstrual cycle, correlation with plasma gonadotropins and ovarian steroids pattern, 629

Symptomatic mucus pattern, menstrual cycle, 629

Symptomatic-hormonal correlations, menstrual cycle, 629

Systemic contraceptive drugs, research activity by U.S. pharmaceutical industry, 1963-1976, 345

- Tampon-spermicide device, 37
- TCu 200 IUD,
 - effect on fibrinolytic activity of uterine fluid, 435
 - effect on plasminogen activators in uterine fluid, 435
 - effect on urokinase-like immunoreactivity in uterine fluid, 435
 - influence on proteinase inhibitors in uterine fluid, 425
- Termination of pregnancy, DL 111-IT (mouse, rat, hamster, dog), 163
- Testosterone, effect on metabolism and motility of spermatozoa, 527
- Testosterone and/or prolactin with p-coumaric acid, effect on mating rate and weight of male reproductive organs (rat), 677
- Testosterone levels,
 - circadian variation during menstrual cycle, 407
 - effect of p-coumaric acid (rat), 677
 - normal menstrual cycle, 301
- Thai women, hormonal changes in normal menstrual cycle, 301
- Thromboembolism, associated with oral contraceptive and fibrinolytic response, 181
- Thyroid function, effect on norethisterone enanthate and norethisterone acetate, 141
- True sterilization failures, pregnancies, 579
- Undernutrition,
 - effect on pharmacokinetics of levonorgestrel (rabbit), 549
 - effect on pharmacokinetics of norethindrone (rabbit), 99
- Unilateral IUD,
 - effect on pregnancy (mouse, rat, rabbit), 543
 - failure in inducing luteolysis (mouse, rat, rabbit), 543
- Urinary excretion of xanthurenic and kynurenic acid after tryptophan load, effect of norethisterone enanthate, 23
- Urokinase-like immunoreactivity in uterine fluid, 435
- Urokinase-like immunoreactivity of uterine-fluid, effect of IUD, 435
- Uterine cytosol progesterone receptor levels, effect of food restriction (undernutrition) (rabbit), 563
- Uterine fluid,
 - cyclic variation of proteinase inhibitors, 425
 - fibrinolytic activity, 435
 - plasminogen activators, 435
 - urokinase-like immunoreactivity, 435


CONTRACEPTION

- Uterine weight, effect of 5α -stigmastane- 3β , $5,6\beta$ -triol-3-monobenzoate (mouse), 315
- Vacuum aspiration, use of 15-methyl-PGF $_{2\alpha}$ methyl ester for cervical dilatation, 251
- Vaginal contraceptive, tampon-spermicide device, 37
- Vaginal ring, estradiol + d-norgestrel, 241
- Vaginal suppository, 15-methyl-PGF $_{2\alpha}$ methyl ester for preoperative cervical dilatation, 251
- Vasectomized men, wives compared with sterilised women on effects of sterilisation, 45
- Viability of spermatozoa, effect of steroid hormones, 527
- Vitamin A level, effect of norethisterone enanthate, 23
- Vitamin supplement, effect during norethisterone enanthate use, 23
- Weight, effect of gossypol and its impurities (male hamster), 653
- WHO (World Health Organization)
- WHO special programme of research, development and research training in human reproduction, 1
- Wives of vasectomized men compared with sterilised women, effects of sterilisation, 45
- Zoapatle plant (Montanoa tomentosa),
antifertility activity, 133
effect on early pregnancy (mouse, rat, hamster, guinea pig), 133

VOL. 23 1981
JANUARY-JUNE
ISSN 0010-7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M. D. — Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

EDITOR

Daniel R. Mishell, Jr., M.D.
Dept. of Obstetrics and Gynecology
University of Southern California School of Medicine
1240 North Mission Road
Los Angeles, California 90033

EDITORIAL ASSISTANTS

Alberta Lawson
Janis H. Torres

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Uwe Goebelsmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduc-
tion & Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior Street
Chicago, Illinois 60611

Sheldon Segal, Ph.D.
Director,
Population Division
Rockefeller Foundation
1133 Avenue of the Americas
New York, New York 10036

William N. Spellacy, M.D.
Professor and Head
Department of Obstetrics
and Gynecology
The Abraham Lincoln
School of Medicine
University of Illinois
Medical Center
840 South Wood Street
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.
Associate Director
Center for Biomedical Research
Rockefeller University
York Avenue & 66th Street
New York, N.Y. 10021

Corresponding Editors for CONTRACEPTION

E. Coutinho, M.D.
Professor
Department of Biochemistry
and Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL

P. G. Crosignani, M.D.
Professor
IV Department of Obstetrics
and Gynecology
University of Milano
Via M. Mellon, 52
20429 Milano, ITALY

E. Diczfalussy, M.D.
Professor
Reprod. Endocrinology
Research Unit
Swedish Med. Research Council
Karolinska Sjukhuset
Stockholm 60, SWEDEN

J. Ferin, M.D.
Professor
Physiology of Human Reprod.
Research Unit
University of Louvain Hosp.
Louvain, BELGIUM

C. Gual, M.D.
Instituto Nacional de la Nutricion
Hospital de Enfermedades de la
Nutricion
Av. San Fernando y
Viaducto Tlalpan
Mexico 22, D.F., MEXICO

I. Hallbrecht, M.D.
Professor
Department of Obstetrics
and Gynecology
Tel Aviv University Med. School
Tel Aviv, ISRAEL

J. Hammerstein, M.D.
Professor
Abt. Gynaek. Endokrinologie
Sterilitat and Familienplanung
Freie Universitat Berlin
Hindenburgdamm 30
1000 Berlin 45
FED. REP. GERMANY

A. A. Haspels, M.D., Prof.
Department of Obstetrics
and Gynecology
Academic Hospital
University of Utrecht
Catharjnesingel 101
Utrecht, NETHERLANDS

T. Luukkainen, M.D.
Steroid Research Laboratory
University of Helsinki
Department of Med. Chemistry
Siltavuorenpenger 10A
SF-00170 Helsinki 17,
FINLAND

J. R. Newton, M.D., Prof.
Birmingham Maternity Hospital
Queen Elizabeth Medical Centre
Edgbaston, Birmingham 15
ENGLAND

Badri N. Saxena, M.D.
Deputy Director General
Indian Council of
Medical Research
Ansari Nagar
New Delhi-110016, INDIA

R. P. Shearman, M.D.
Professor of Obstetrics
and Gynecology
The University of Sydney
Sydney 2006, N.S.W.
AUSTRALIA

M. Vessey, M.D.
Professor, University Dept. of
Social & Community Med.
University of Oxford
8 Keble Road
Oxford, OX13QN
ENGLAND

J. Zanartu, M.D.
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clinica
Obstetrica
Hospital Jose Joaquin Aguirre
Casilla 6637
Santiago, CHILE

GUIDE FOR AUTHORS

CONTRACEPTION invites concise reports of original research in the experimental and clinical aspects of all areas of contraception. The purpose of this journal is to provide a medium for the rapid communication of advances and new knowledge in this important field. The Editor anticipates receiving manuscripts from workers in the following areas of research: chemistry, biochemistry, physiology, endocrinology, biology, the medical sciences and demography. Publication of original papers within 90 days of manuscript receipt is planned. Authors will be advised of disposition of the manuscript within 30 days of receipt. Manuscripts should be sent to:

Daniel R. Mishell, Jr., M.D., Editor
Department of Obstetrics and Gynecology
University of Southern California School of Medicine
Women's Hospital, Room L1009
1240 North Mission Road
Los Angeles, California 90033

Authors outside the United States should address manuscripts to a corresponding editor in their own country. Authors in countries not represented by a corresponding editor should send their manuscripts directly to The Editor.

Preparation of Manuscript - (See next page)

CONTRACEPTION

January 1981

Volume 23, Number 1

Chemical Methods for Male Fertility Control Nieschlag, E., Wickings, E.J. and Breuer, H.....	1
Low Dose Injectable Contraceptive Norethisterone Enanthate 20 mg Monthly - I. Clinical Trials Prema, K., Gayathri, T.L., Ramalakshmi, B.A., Madhavapeddi, R. and Philips, F.S.....	11
Low Dose Injectable Contraceptive Norethisterone Enanthate 20 mg Monthly - II. Metabolic Side Effects Bamji, M.S., Safaya, S. and Prema, K.....	23
Experience With a Tampon-Spermicide Device Page, E.W.....	37
The Effects of Sterilisation: A Comparison of Sterilised Women With the Wives of Vasectomized Men Alder, E., Cook, A., Gray, J., Tyrer, G., Warner, P., Bancroft, J., Loudon, N.B. and Loudon, J.....	45
The Effect of Daily d-Norgestrel (30 ug) on Serum Progesterone in Thai Women Sriyatta, B., Vathanasiritham, P., Snidvongs, W. and Jantaraniyom, K.....	55
Contraception With Subcutaneous Capsules Containing ST-1435. Pituitary and Ovarian Function and Plasma Levels of ST-1435. Lähtenmäki, P., Weiner, E., Lähtenmäki, P., Johansson, E. and Luukkainen, T.....	63
Norethisterone Enanthate as an Injectable Contraceptive in Puerperal and Non-Puerperal Women Melis, G.B., Strigini, F., Fruzzetti, F., Paoletti, A.M., Rainer, E., Düsterberg, B. and Fioretti, P.....	77
The Rabbit as an Animal Model to Study Pharmacokinetics of Levonorgestrel in Women Nair, K.M., Sivakumar, B. and Rao, B.S.N.....	89
Effect of Food Restriction (Undernutrition) on Pharmacokinetics of Norethindrone in Rabbits Prasad, K.V.S., Sivakumar, B. and Rao, B.S.N.....	99

CONTRACEPTION

February 1981

Volume 23, Number 2

Studies on Ovarian and Adrenal Steroids at Different Phases of the Menstrual Cycle.

I. Dynamic Changes During the Periovalutary Period

Aedo, A.-R., Landgren, B.-M. and Diczfalusy, E.....107

Studies on the Enzymatic Cleavage of Norethisterone Oenanthate

Back, D.J., Breckenridge, A.M., Chapman, C.R., Crawford, F.E., Olsen, K.A.,
Orme, M.L'E. and Rowe, P.H.....125

Antifertility Activity of Montanoa tomentosa (Zoapatle)

Hahn, D.W., Ericson, E.W., Lai, M.T. and Probst, A.....133

Phase I Clinical Trial of Two Contraceptive Preparations. Norethisterone Enanthate (NEN) and Norethisterone Acetate (NET)

Andino, N.....141

The Antigonadotropic Activity of Lithospermum ruderae. II. The Inhibition of LRF-Induced Gonadotropin Release in vitro

Findley, W.E.....157

A New Non-Hormonal Pregnancy-Terminating Agent

Galliani, G., Assandri, A., Gallico, L., Luzzani, F., Oldani, C., Omodei-Sale, A.,
Soffientini, A. and Lancini, G.....163

Fibrinolytic Response and Oral Contraceptive Associated Thromboembolism

Pizzo, S.V., Lewis, J.G., Campbell, E.E. and Dreyer, N.A.....181

Influence of the LH-RH Analogue Buserelin on Cyclic Ovarian Function and on Endometrium. A New Approach to Fertility Control?

Schmidt-Gollwitzer, M., Hardt, W., Schmidt-Gollwitzer, K., von der Ohe, M. and
Nevinny-Stickel, J.....187

Plasma Levels of Levonorgestrel in Women During Longterm Use of Norplant

Croxatto, H.B., Diaz, S., Miranda, P., Elamsson, K. and Johansson, E.D.B.....197

Correlation Between the Serum Norethindrone (NET) Levels Attained After Insertion of a Silastic Implant Releasing Norethindrone Acetate and the Endogenous Hormones Particularly Progesterone

Laumas, V., Jain, A.K., Jha, P., Rahman, S.A., Kumar, D., Malik, B.K., Sarkar, N.N.,
Takkar, D., Hingorani, V. and Laumas, K.R.....211

Announcements.....227

The Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Women: Studies with Ovran and Ovranette	
Back, D., Bates, M., Breckenridge, A., Hall, J., MacIver, M., Orme, M., Park, B. and Rowe, P.	229
Clinical Performance and Endocrine Profiles with Contraceptive Vaginal Rings Containing a Combination of Estradiol and D-Norgestrel	
Mehta, S., Joshi, U., Sankolli, G., Adatia, A., Donde, U. and Saxena, B.	241
Vaginal Administration of 15-Methyl-PGF _{2α} Methyl Ester for Preoperative Cervical Dilatation	
WHO Task Force on Prostaglandins for Fertility Regulation	251
Fluid-Filled Silastic Capsules: A New Approach to a More Constant Steroidal Drug Delivery System	
Kumar, D., Farooq, A. and Laumas, K.	261
Hormonal Effects of the 300µg Norethisterone (NET) Minipill. 3. Comparison of the Short-Term (2nd Month) and Medium-Term (6th Month) Effects in 21 Subjects	
Landgren, B.-M., Lager, S. and Diezfallus, E.	269
Hormonal Changes in Normal Menstrual Cycle of Thai Women	
Werawatgoompa, S., Tankeyoon, M., Kongseripong, R., Chaniyom, K., Virutamasen, P., Dusitsin, N. and Boonsiri, B.	301
Biological Profile of the Steroid 5α-Stigmastane-3β,5,6β-Triol-3-Monobenzoate	
Pakrashi, A. and Chakrabarty, S.	315
On the Mechanism of Action of a New Pregnancy-Terminating Agent. Part I: Effects on Prostaglandin F _{2α} Metabolism in the Rat and the Hamster	
Luzzani, F. and Galliani, G.	325
Evaluation of STS-557 as a Postcoital Contraceptive in the Baboon	
Castracane, V. and Goldzieher, J.	335
Announcement	341
Announcement	343

Research Activity on Systemic Contraceptive Drugs by the U.S. Pharmaceutical Industry, 1963-1976 DiRaddo, J. and Wardell, W.M.	345
Contraceptives and the Conceptus. II. Sex of the Fetus and Neonate After Oral Contraceptive Use Klinger, H.P. and Glasser, M.	367
The Effect of Depot-Medroxyprogesterone Acetate on the Fetus and Nursing Infant: A Review Schwallie, P.C.	375
Long-Term Clinical Experience with the Cu-7-IUD. Evaluation of a Prospective Study Larsson, B., Hagström, B., Viberg, L. and Hamberger, L.	387
Serum 25-Hydroxycholecalciferol Levels in Women Using Oral Contraceptives Schreurs, W.H.P., van Rijn, H.J.M. and van den Berg, H.	399
Studies on Ovarian and Adrenal Steroids at Different Phases of the Menstrual Cycle: II. A Comparative Assessment of the Circadian Variation in Steroid and Lutropin Levels During the Follicular, Periovulatory and Luteal Phases Aedo, A.-R., Landgren, B.-M. and Diczfalusy, E.	407
Cyclic Variation of Proteinase Inhibitors in Human Uterine Fluid and Influence of an IUD Casslén, B. and Ohlsson, K.	425
Effect of IUD on Urokinase-Like Immunoreactivity and Plasminogen Activators in Human Uterine Fluid Casslén, B., Thorell, J. and Astedt, B.	435
Comparison of Plasma and Myometrial Tissue Concentrations of Estradiol-17 β and Progesterone in Nonpregnant women Akerlund, M., Batra, S. and Helm, G.	447
Effect of Inhibition of Histidine Decarboxylase on Implantation in the Mouse Cox, C., Mukerjee, S., Jackson, M. and Dey, S.K.	457

A Randomized Study of Metabolic Effects of Four Low-Estrogen Oral Contraceptives: I. Results After 6 Cycles M. Briggs and M. Briggs.....	463
Intracervical Release of Levonorgestrel for Contraception H. Kurunmäki, J. Toivonen, P. Lähteenmäki and T. Luukkainen.....	473
Pharmacokinetics of Ethinyloestradiol in Women from Different Populations K. Fotherby, J. Akpoviro, H.A. Abdel-Rahman, H.K. Topozada, J.C. de Souza, E.M. Coutinho, S. Koetsawang, P. Nukularn, U.K. Sheth, M.K. Mapa, S. Gopalan, E.R. Plunkett, P.F. Brenner, M.V. Hickey, E.S. Grech, R. Lichtenberg, C. Gual, R. Molina, C. Gomez-Rogers, E. Kwon, S.W. Kim, T. Chan, S.S. Ratnam, B.M. Landgren, R.P. Shearman, J.W. Goldzieher and T.S. Dozier.....	487
Plasma Levels of Norethindrone in Indian Women Receiving Norethindrone Enanthate (20 mg) Injectable K.V.S. Prasad, K.M. Nair, B. Sivakumar, K. Prema and B.S.N. Rao.....	497
Electrolyte Interactions in Cervical Mucus and Their Relationship to Circulating Hormone Levels K.G. Gould and A.H. Ansari.....	507
Factors Associated with Family Planning Acceptance in Bangkok Metropolis Health Clinic Areas (MHCs) T. Chumnijarakij, R.A. Grossman, Y. Onthum and N. Debavalya.....	517
Effect of Steroid Hormones on the Metabolism of Human Spermatozoa N.P. Trifunac and G.S. Bernstein.....	527
Intrauterine Contraceptive Devices: Failure of Unilateral Intrauterine Device in Inducing Luteolysis in Rabbits, Rats and Mice W.S. Al-Amood, E. Al-Khateeb, R. Chatterjee (Basu) and A. Chatterjee.....	543
Effect of Food Restriction (Undernutrition) on Pharmacokinetics of Levonorgestrel in Rabbits K.M. Nair, B. Sivakumar and B.S.N. Rao.....	549
Effect of Food Restriction (Undernutrition) on Plasma Sex Hormone Binding Globulin (SHBG) Capacity, Liver Drug Metabolizing Enzymes and Uterine Cytosol Progesterone Receptor Levels in Rabbits K.V.S. Prasad, K.M. Nair, B. Sivakumar and B.S.N. Rao.....	563
Announcement.....	577

Luteal Phase Pregnancies in Female Sterilization Patients I.-C. Chi and P.J. Feldblum.....	579
Menstrual Blood Loss in Healthy Chinese Women G. Ji, L.-Y. Ma, S. Zeng, H.-M. Fan and L.-H. Han.....	591
A Two-Year Follow-Up Study of Women Sterilized in India R.V. Bhatt, S. Pachauri, K. Jariwala and L.N. Chauhan.....	603
Abortion During Mid-Pregnancy by Rivanol-Catheter Supplemented with PGF _{2α} Drip-Infusion or Quinine Hydrochloride Y. Manabe and A. Manabe.....	621
Correlation of Plasma Gonadotrophins and Ovarian Steroids Pattern with Symptomatic Changes in Cervical Mucus During the Menstrual Cycle in Normal Cycling Women S. Cortesi, G. Rigoni, F. Zen and R. Sposetti.....	629
Blood Levels of Ethynylestradiol, Caffeine, Aldosterone and Desoxycorticosterone in Hypertensive Oral Contraceptive Users L. Kaul, C.L. Curry and B.S. Ahluwalia.....	643
Antifertility Effects of Gossypol and Its Impurities on Male Hamsters D.P. Waller, H.H.S. Fong, G.A. Cordell and D.D. Soejarto.....	653
Formation of Compounds with Antigonadotropic Activity from Inactive Phenolic Precursors H.G. Gumbinger, H. Winterhoff, H. Sourgens, F.H. Kemper and R. Wylde.....	661
The Effect of Intrauterine Injection of Concanavalin A on Implantation in Mice and Rats J.T. Wu and Z. Gu.....	667
3-(4-Hydroxy Phenyl)-2-Propenoic Acid — A Reproductive Inhibitor in Male Rat A. Pakrashi, S.N. Kabir and H. Ray.....	677
Author Index for Volume 23.....	687
Subject Index for Volume 23.....	691



CONTRACEPTION

INDEX TO VOLUME 24

AUTHOR INDEX

- | | |
|-------------------------|------------------------------|
| Aedo, A.-R., 117, 543 | Cohen, B.L., 159 |
| Åhren, T., 415, 451 | Comaru-Schally, A.M., 315 |
| Åkerlund, M., 195 | Coy, D., 275 |
| Allonen, H., 529 | Coy, D.H., 315 |
| Alvarez, F., 469 | Creange, J.E., 289 |
| Asch, R.H., 275 | Das, C., 83 |
| Aznar, R., 235 | Davies, A.M., 1 |
| Ballard, C.A., 145, 151 | Diczfaluzi, E., 29, 117, 543 |
| Balmaceda, J.P., 275 | Düsterberg, B., 673 |
| Baras, M., 1 | Elder, M., 15 |
| Bardin, C.W., 321 | Faundes, A., 393, 469 |
| Benagiano, G., 493 | Flickinger, G.L., 259 |
| Boettcher, B., 183 | Ford, W.C.L., 577 |
| Borin, K., 173 | Fotherby, K., 15 |
| Born, H.-J., 61 | Franz, I., 61 |
| Brache, V., 469 | Fraser, H.M., 647 |
| Breneman, W.R., 77 | Fraser, I., 493 |
| Brenner, P.F., 617 | Gal-Or, L., 657 |
| Bye, P.G., 15 | Ganguly, M., 229 |
| Bygdeman, M., 45 | Gilman, N.J., 301 |
| Canales, E.S., 315 | Gonen, R., 657 |
| Casagrande, J., 429 | Green, K., 45 |
| Cassle, B., 685 | Grossman, R.A., 245 |
| Chandra, H., 269 | Gupta, U., 283 |
| Chang, M.C., 203 | Hahn, D.W., 97 |
| Chappel, S.C., 259 | Hardy, E., 393 |
| Charumilind, P., 245 | Harlap, S., 1 |
| Chaudhury, R.R., 283 | Higgins, J.E., 631 |
| Cheng, C.Y., 183 | Homm, R., 97 |
| Christensen, N.J., 45 | Howard, G., 15 |
| Chumnijarakij, T., 245 | Hümpel, M., 673 |

CONTRACEPTION

- International Comparative Trial,
341, 359, 377
- Jackanicz, T.M., 323
- Johansson, E.D.B., 415, 451
- Jailkhani, B.L., 83
- Johnson, A.N., 97
- Kanjanapothi, D., 559
- Katz, M., 159
- Kaufman, J.M., 589
- Kerr-Wilson, R.H.J., 647
- Kobayashi, T.K., 685
- Kobylec, 195
- Krauss, R.M., 429
- Kuhl, H., 61
- Landgren, B.-M., 29, 117, 543
- Lau, I.F., 107, 203
- Laudański, T., 195
- Lee, C.-S., 569
- Leon, P., 469
- Levi, C., 235
- Lindgren, S., 137
- Lozano, M., 235
- Luukkainen, T., 529
- MacKenzie, L., 647
- Malaviya, B., 269
- Malhotra, N., 283
- Manabe, A., 53
- Manabe, Y., 53
- Marrs, R.P., 617
- Mishell, D.R., Jr., 429, 481, 617, 635
- Moghissi, K.S., 173
- Mohsenian, M., 173
- Moodbidri, S.B., 695
- Munshi, S.R., 695
- Muttamara, S., 245
- Nandedkar, T.D., 695
- Nygren, K.-G., 529
- Onthuam, Y., 245
- Oriowo, M.A., 29
- Panthong, A., 559
- Pastene, L., 393
- Pike, M.C., 429
- Portes-Carrasco, R., 393
- Potts, G.O., 289
- Probst, A., 97
- Pyörälä, T., 529
- Rattanapanone, V., 559
- Reddy, P.R.K., 215
- Reyes, Q., 393
- Robertson, D.N., 469
- Roy, S., 429, 481, 617, 635
- Rukmini, V., 215
- Rusticus, C., 97
- Saksena, S.K., 107, 203
- Salmonsén, R., 107, 203
- Sang, G.W., 15
- Sarvamangala, B.S., 695
- Schally, A.V., 275, 315
- Schane, H.P., 289
- Scharf, M., 657
- Schneider, M., 61
- Shelton, J.D., 631
- Shirley, S., 301
- Sivin, I., 469
- Smitasiri, Y., 559
- Södersberg, G., 137

CONTRACEPTION

- Speck, U., 673
Stern, J., 469
Sthory, I., 315
Stiber, A.J., 603
Stormby, N., 685
Stowe, S.M., 301
Taesotikul, T., 559
Talwar, G.P., 83
Tandon, A., 83
Taubert, H.-D., 61
Thiery, M., 589
Tso, W.-W., 569
Turkel, J., 603
Varma, S.K., 283
Vermeulen, A., 589
Vessby, B., 451
Victor, A., 415, 451
Vijayalashmi, S., 695
Waites, G.M.H., 577
Wan, L.S., 229, 603
Weiner, J.M., 301
Weiss, G., 229
Wilkins, J., 481
Wolf, R.M., 301
Wu, Y.-M., 259
Zamora, G., 235
Zarate, A., 315
Zeller, F.J., 77
Zheng, S., 45
Zilberman, A., 657



INDEX TO VOLUME 24 SUBJECT INDEX

- Abortifacient results, (15S)-15-methyl PGF_{2 α} methyl ester, 617
- Abortion,
 - intramuscular injections of Sulprostone, 145
 - vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 151
- Absorption,
 - norethisterone oenanthate, 15
 - vaginal device releasing norethisterone, 29
- Acceptability,
 - CVR, 393
 - follow-up survey of CVR, 393
- Acceptors, CVR, 393
- Access to pertinent data, oral contraceptives and risk of cancer, 301
- Accessory sexual glands,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of norethindrone enanthate (rat), 61
- Acetylsalicylic acid, effect of intrauterine administration on implantation (rat), 283
- ACTH (adrenocorticotrophic hormone)
- ACTH stimulation following dexamethasone suppression, effect of medroxyprogesterone acetate, 543
- Acute salpingitis, influence of IUD on course of disease, 137
- Adrenal and ovarian steroids, different phases of menstrual cycle, 117, 543
- Adrenal function, effect of medroxyprogesterone acetate, 543
- Adrenal gland weight,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of norethindrone enanthate (rat), 61
- Adrenocorticotrophic hormone (ACTH), effect on Win 32,729 action, 289
- Aldolase activity, effect of 6-chloro-6-deoxyglucose (rat), 577
- Androgenic effect, dimeric ethynodiol-testosterone ester (rat), 61
- Androstenedione, effect of medroxyprogesterone acetate on plasma level, 117, 543
- Anovulatory effect, LHRH antagonist, 315
- Antibodies generated by Pr- β -hCG-TT, effect on terminating pregnancy (baboon), 83
- Antifertility effect, Mentha arvensis plant extract (rat), 559

CONTRACEPTION

- Antifertility studies, gossypol (mouse, rat), 97
- Antigonadotropic activity, *Mentha arvensis* plant extract (rat), 559
- Antiprostaglandin drugs, effect of intrauterine administration on implantation (rat), 283
- Antiserum to FSH, effect on ovulation and implantation (mouse), 695
- Apo A-I (apolipoprotein A-I)
- Apo B (apolipoprotein B)
- Apolipoprotein B and A-I concentrations,
 CVR releasing estradiol + levonorgestrel, 451
 ethinylestradiol + levonorgestrel, 451
- Average daily release, estradiol and levonorgestrel from CVRs, 323
- Bacteriologic comparison of vaginal cultures,
 before and after CVR releasing estradiol + levonorgestrel, 481
 before and after ethinyl estradiol + levonorgestrel, 481
- Bangkok Metropolis Health Clinics, study of contraceptive choice and use, 245
- Basal body temperature (BBT), effect of ethinyl estradiol + norgestimate, 173
- BBT (basal body temperature)
- BBT and Ovutron^R readings, correlation with sex-hormone and LH levels, 635
- Beagle dog toxicology, medroxyprogesterone acetate, 493
- Bioavailability, cyproterone acetate, 673
- Bioavailability, cyproterone acetate (rat, beagle, monkey), 673
- Bioavailability, Gestodene, 673
- Bioavailability, Gestodene (rat, beagle, monkey), 673
- Bioavailability, levonorgestrel, 673
- Bioavailability, levonorgestrel (rat, beagle, monkey), 673
- Bioavailability, norethisterone, 673
- Bioavailability, norethisterone (rat, beagle, monkey), 673
- Bioavailability of norethisterone, after norethisterone oenanthate, 15
- Bleeding and pain, Nova-T and copper-T-200, 529
- Bleeding and spotting days,
 effect of CVR releasing estradiol + levonorgestrel, 377
 effect of ethinylestradiol + levonorgestrel, 377
- Bleeding pattern,
 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45
 (15S)-15-methyl PGF₂ α methyl ester, 603
 vaginal device releasing norethisterone, 29
- Blood loss, 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45

- Blood pressure changes,
 - CVR releasing estradiol + levonorgestrel, 359
 - ethinylestradiol + levonorgestrel, 359
- Body weight,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of gossypol (hamster), 259
 - effect of gossypol (rabbit), 203
 - effect of norethindrone enanthate (rat), 61
- Breast-fed infant, effect of medroxyprogesterone acetate, 493
- Cancer risk and oral contraceptives, access to data and information explosion, 301
- Carbohydrate metabolism,
 - CVR releasing estradiol + levonorgestrel, 415
 - effect of medroxyprogesterone acetate, 493
 - ethinylestradiol + levonorgestrel, 415
- Cell count in uterine fluid, effect of IUD, 685
- Cellular composition of uterine fluid, effect of IUD, 685
- Cervical dilatation, Nelaton catheter vs. laminaria, 53
- Cervical mucus, effect of ethinyl estradiol + norgestimate, 173
- Cervical mucus properties, effect of ethinyl estradiol + norgestimate, 173
- Cervical mucus score, effect of ethinyl estradiol + norgestimate, 173
- Chlormadinone acetate, effect on forward migration of spermatozoa, 183
- 6-Chloro-6-deoxyglucose,
 - effect of high doses (rat), 577
 - effect on aldolase activity (rat), 577
 - effect on glucose oxidation (rat), 577
 - effect on glyceraldehyde-3-phosphate dehydrogenase activity (rat), 577
 - production of spermatocoeles (rat), 577
 - toxicity trial (rat), 577
- CHOL (cholesterol)
- CHOL/HDL-C, effect of CVR releasing estradiol + levonorgestrel on serum level,
 - 429, 469
- Cholesterol (CHOL),
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 429,
 - 451, 469
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- Clinical observations,
 - CVR releasing estradiol + levonorgestrel, 415, 451

CONTRACEPTION

- ethinylestradiol + levonorgestrel, 415, 451
- Clinical performance, comparative trial with Nova-T and copper-T-200, 529
- Commentary on article "Depo-Provera, a critical analysis", 493
- Complications,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 151
 - intramuscular injections of Sulprostone, 145
 - Nelaton catheter vs. laminaria, 53
- Complications of pregnancy and labor, former use of oral contraceptives, 1
- Continuation rate,
 - CVR releasing estradiol + levonorgestrel, 341
 - ethinylestradiol + levonorgestrel, 341
 - Nova-T and copper-T-200, 529
- Contraception and toxic-shock syndrome, 631
- Contraceptive choice and use, Bangkok Metropolis Health Clinics, 245
- Contraceptive effectiveness,
 - CVR releasing estradiol + levonorgestrel, 341
 - ethinylestradiol + levonorgestrel, 341
- Contraceptive method, effect on relative risk of toxic-shock syndrome, 631
- Contraceptive vaginal ring (CVR), acceptability, 393
- Contraceptive vaginal ring, releasing estradiol + levonorgestrel, 323
- Contraceptive vaginal sponge, 235
- Copper ions, influence on uterine activity (rabbit), 195
- Copper-based IUD with gold or platinum core,
 - estimation of cost, 657
 - in vitro and in vivo studies, 657
 - metallographic examination, 657
 - preparation of coated wires, 657
 - weight loss experiments, 657
- Copper-releasing IUD,
 - copper-T-200, 529
 - Nova-T, 529
- Copper-T-200,
 - clinical performance, 529
 - cumulative rates, 529
- Cortisol, effect of medroxyprogesterone acetate on plasma level, 117, 543
- Cumulative rates, Nova-T and copper-T-200, 529
- CVR (contraceptive vaginal ring)

- CVR releasing estradiol + levonorgestrel,
 - effect on lipids and lipoproteins, 429
 - effect on serum lipoproteins and apolipoproteins, 451
 - effect on vaginal flora, 481
 - lipoprotein patterns, 469
 - metabolic effects, 415, 451
 - multicenter study of menstrual patterns, 377
 - multicenter study of subjective and objective measures of effects, 359
 - multicenter study of use effectiveness, 341
- Cyproterone acetate, terminal half-life and bioavailability, 673
- Cyproterone acetate, terminal half-life and bioavailability (rat, beagle, monkey), 673
- D-Ser(Bu)^t₆ de Gly LHRH ethylamide, effects on endometrium and ovaries (monkey), 647
- Data access, oral contraceptives and risk of cancer, 301
- Dehydroepiandrosterone, effect of medroxyprogesterone acetate on plasma level, 117, 543
- 9-Deoxo-16,16-dimethyl-9-methylene PGE₂,
 - self-administration for termination of early pregnancy, 45
 - vaginal administration for second trimester abortion, 151
- "Depo-Provera, a critical analysis", commentary on the article, 493
- Dexamethasone suppression and subsequent ACTH stimulation, effect of medroxyprogesterone acetate, 543
- Diffusion of estradiol and levonorgestrel from CVRs, 323
- α-Difluoromethylornithine, antifertility effect (rat), 215
- 20 α-Dihydroprogesterone, effect of RMI-12,936 on circulating level (rabbit), 107
- Dihydrotestosterone, effect of medroxyprogesterone acetate on plasma level, 117, 543
- Dilatation of cervix, Nelaton catheter vs. laminaria, 53
- Dimeric ethynodiol-testosterone ester, effect on spermatogenesis (rat), 61
- Discontinuation of treatment,
 - CVR, 393
 - CVR releasing estradiol + levonorgestrel, 451
 - ethinylestradiol + levonorgestrel, 451
- Early gestation termination, (15S)-15-methyl PGF₂ α methyl ester, 617
- Early pregnancy termination, self-administration of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45
- Editorial comment, CVR releasing estradiol + levonorgestrel, 321
- Egg transport,
 - effect of medroxyprogesterone acetate (rabbit), 107

CONTRACEPTION

- effect of RMI-12,936 (rabbit), 107
- effect of testosterone enanthate (rabbit), 107
- Electron transport chain segments of spermatozoal mitochondria, effect of gossypol (boar), 569
- Elimination, norethisterone and norethisterone oenanthate, 15
- Endocrine studies, gossypol (rat), 97
- Endocrinological effects, gossypol (rabbit), 203
- Endometrial glandular cells in uterine fluid, effect of IUD, 685
- Endometrium,
 - effect of chronic LHRH agonist treatment (monkey), 647
 - effect of LHRH antagonist, 315
 - effect of medroxyprogesterone acetate, 493
- Eididymal weight,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of gossypol (rabbit), 203
 - effect of norethindrone enanthate (rat), 61
- Estradiol,
 - effect of chronic LHRH agonist treatment on serum level (monkey), 647
 - effect of ethinyl estradiol + d-norgestrel on serum level, 159
 - effect of gossypol on ovarian and serum concentrations (hamster), 259
 - effect of LHRH antagonist on serum level, 315
 - effect of medroxyprogesterone acetate on plasma level, 117, 543
 - in vitro release from CVR, 323
- Estradiol + levonorgestrel,
 - effect on carbohydrate metabolism, 415
 - effect on lipids and lipoproteins, 429
 - effect on lipoprotein patterns, 469
 - effect on liver function, 415
 - effect on serum lipoproteins and apolipoproteins, 451
 - effect on vaginal flora, 481
 - improved CVR design, 323
 - metabolic effects, 415, 451
 - multicenter study of menstrual patterns, 377
 - multicenter study of subjective and objective measures of effects, 359
 - multicenter study of use effectiveness, 341
- Estrogenic activity, Mentha arvensis plant extract (rat), 559
- Estrogens, effect of LH-RH antagonist on serum concentration (monkey), 275

- Estrone, effect of gossypol on ovarian and serum concentrations (hamster), 259
- 17 α -Ethinyl-13-ethyl-17 β -hydroxy-4,15-gonadien-3-one (Gestodene),
 - terminal half-life and bioavailability, 673
 - terminal half-life and bioavailability (rat, beagle, monkey), 673
- Ethinylestradiol + levonorgestrel,
 - effect on carbohydrate metabolism, 415
 - effect on liver function, 415
 - effect on serum lipoproteins and apolipoproteins, 451
 - effect on vaginal flora, 481
 - metabolic effects, 415, 451
- Ethinylestradiol + lynestrenol, plasma levels of ethinylestradiol, 589
- Ethinyl estradiol + norethindrone, effect on pituitary response to LHRH stimulation, 229
- Ethinyl estradiol + norethindrone acetate, effect on pituitary response to
 - LHRH stimulation, 229
- Ethinyl estradiol + norgestimate, effect on cervical mucus, 173
- Ethinyl estradiol + d-norgestrel,
 - effect on pituitary and ovarian function, 159
 - effect on pituitary response to LHRH stimulation, 229
 - plasma levels of ethinylestradiol, 589
- Ethinylestradiol plasma levels,
 - after ethinylestradiol-containing pills, 589
 - effect of different commercial preparations, 589
 - ethinylestradiol + d-norgestrel treatment, 589
- Ethinylestradiol-containing pills, plasma levels of ethinylestradiol, 589
- Ethinyl oestradiol, effect on forward migration of spermatozoa, 183
- Ethinodiol diacetate, effect on forward migration of spermatozoa, 183
- Ethinylestradiol + levonorgestrel,
 - multicenter study of menstrual patterns, 377
 - multicenter study of subjective and objective measures of effects, 359
 - multicenter study of use effectiveness, 341
- Expulsion, Nova-T and copper-T-200, 529
- Factors associated with choice, contraceptive choice and use, 245
- Fertility,
 - after termination of pregnancy by Pr- β hCG-TT antibodies, 83
 - effect of α -difluoromethylornithine (rat), 215
 - effect of gossypol (hamster), 259
 - effect of gossypol (mouse, rat, hamster), 97

CONTRACEPTION

- effect of gossypol (rabbit), 203
- Fertility recovery, effect of gossypol (rat, hamster), 97
- Fertilization, effect of RMI-12,936 (rabbit), 107
- Field acceptability, CVR, 393
- First trimester abortion, intramuscular injections of Sulprostone, 145
- Follicle stimulating hormone (FSH),
 - effect of ethinyl estradiol + d-norgestrel on serum level, 159
 - effect of gossypol on pituitary and serum concentrations (hamster), 259
 - effect of inhibin on plasma level (mouse), 695
 - effect of LHRH antagonist on serum level, 315
- Follow-up survey, acceptability of CVR, 393
- Former oral contraceptive users, complications of pregnancy and labor, 1
- Forward migration of spermatozoa, effects of steroids, 183
- FSH (follicle stimulating hormone)
- FSH and FSH response to GnRH, effect of ethinyl estradiol + d-norgestrel, 159
- FSH response, LHRH stimulation during oral contraceptive use, 229
- General damage, effect of medroxyprogesterone acetate, 493
- Gestodene (17 α -ethinyl-13-ethyl-17 β -hydroxy-4,15-gonadien-3-one)
- Glucosamine-6-phosphate synthase, effect of α -difluoromethylornithine on level in uterus (rat), 215
- Glucose oxidation, effect of 6-chloro-6-deoxyglucose (rat), 577
- Glucose tolerance tests,
 - effect of CVR releasing estradiol + levonorgestrel, 415
 - effect of ethinylestradiol + levonorgestrel, 415
- Glyceraldehyde-3-phosphate dehydrogenase activity, effect of 6-chloro-6-deoxyglucose (rat), 577
- GnRH (gonadotropic releasing hormone)
- Gold or platinum core copper-based IUD, in vitro and in vivo studies, 657
- Gonadotropic releasing hormone (GnRH), gonadotropic responses during use of ethinyl estradiol + d-norgestrel, 159
- Gossypol,
 - antifertility and endocrine activities (mouse, rat, hamster), 97
 - effect on fertility (hamster), 259
 - effect on ovulation (hamster), 259
 - effect on pituitary-ovarian endocrine function (hamster), 259
 - effect on spermatozoal electron transport chain segments (boar), 569
 - effect on spermatozoal respiration (boar), 569

- toxicological and endocrinological effects (rabbit), 203
- Granulocytes in uterine fluid, effect of IUD, 685
- hCG (human chorionic gonadotropin)
 - β -hCG plasma level,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45
 - (15S)-15-methyl PGF₂ α methyl ester, 603, 617
- HDL (high density lipoproteins)
- HDL subfractions, effect of CVR releasing estradiol + levonorgestrel on serum level, 429
- HDL-C (high density lipoprotein cholesterol)
- HDL-C/apo A-I,
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 451
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- Hemoglobin and erythrocyte volume fraction,
 - effect of CVR releasing estradiol + levonorgestrel, 415
 - effect of ethinylestradiol + levonorgestrel, 415
- Hemoglobin changes,
 - CVR releasing estradiol + levonorgestrel, 359
 - ethinylestradiol + levonorgestrel, 359
- Hemoglobin values, 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45
- High density lipoprotein cholesterol (HDL-C),
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 429, 451, 469
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- High density lipoproteins (HDL),
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 429, 451
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- Human chorionic gonadotropin (hCG)
- 17-Hydroxypregnenolone, effect of medroxyprogesterone acetate on plasma level, 117, 543
- 17-Hydroxyprogesterone, effect of medroxyprogesterone acetate on plasma level, 117, 543
- Hypertensive disease of pregnancy, former use of oral contraceptives, 1
- Ibuprofen, effect of intrauterine administration on implantation (rat), 283
- Immunosuppressive effects, medroxyprogesterone acetate, 493
- Implantation,
 - effect of antiserum to FSH (mouse), 695

CONTRACEPTION

- effect of inhibin (mouse), 695
- effect of intrauterine administration of antiprostaglandin drugs (rat), 283
- Indomethacin, effect of intrauterine administration on implantation (rat), 283
- Infection, Nova-T and copper-T-200, 529
- Information explosion, oral contraceptives and risk of cancer, 301
- Information processing techniques, 301
- Informing the medical community, medroxyprogesterone acetate, 493
- Inhibin, effect on ovulation and implantation (mouse), 695
- Injectable contraceptives,
 - medroxyprogesterone acetate, 117, 493, 543
 - norethisterone oenanthate, 15
 - study of contraceptive choice and use, 245
- Interceptive agent, Win 32,729 (rat, monkey), 289
- Intermediate density lipoproteins (IDL), effect of CVR releasing estradiol + levonorgestrel on serum level, 429
- Intramuscular injections of Sulprostone, first and midtrimester abortion, 145
- Intraperitoneal quinaacrine hydrochloride, toxic effects (monkey), 269
- Intrauterine administration of antiprostaglandin drugs, effect on implantation (rat), 283
- Intrauterine device (IUD),
 - copper-based with gold or platinum core, 657
 - copper-T-200, 529
 - effect on cellular composition of uterine fluid, 685
 - influence on course of acute salpingitis, 137
 - Nova-T, 529
 - study of contraceptive choice and use, 245
 - TCu 200, 685
- Intrauterine instillation of CuCl_2 , effect on uterine activity, 195
- Intrauterine quinaacrine hydrochloride, toxic effects (monkey), 269
- Intravenous quinaacrine hydrochloride, toxic effects (monkey), 269
- IUD (intrauterine device)
- Karyopyknotic index of vaginal cytology, effect of ethinyl estradiol + norgestimate, 173
- Labor complications, former use of oral contraceptives, 1
- Laminaria vs. Nelaton catheter, cervical dilatation, 53
- LDL-C (low density lipoprotein cholesterol)
- LDL-C/apo B,
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 451

- effect of ethinylestradiol + levonorgestrel on serum level, 451
- LDL-C/HDL-C,
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 451
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- Levonorgestrel,
 - in vitro release from CVR, 323
 - terminal half-life and bioavailability, 673
 - terminal half-life and bioavailability (rat, beagle, monkey), 673
- LH (luteinizing hormone or lutropin)
- LH and LH response to GnRH, effect of ethinyl estradiol + d-norgestrel, 159
- LH response, LHRH stimulation during oral contraceptive use, 229
- LHRH (luteinizing hormone releasing hormone)
- LHRH activity, effect of Lithospermum plant extract (chick), 77
- LHRH agonist, D-Ser(Bu)^t₆ des Gly LHRH ethylamide, 647
- LHRH antagonist,
 - NAc-D-p-Cl-Phe^{1,2}, D-Trp³, D-Phe⁶, D-Ala¹⁰-LHRH, 315
 - (N-Ac-D-Trp^{1,3}, D-p-Cl-Phe², D-Phe⁶, D-Ala¹⁰)-LH-RH, 275
- LHRH stimulation, pituitary response with oral contraceptive use, 229
- Lipid and lipoprotein lipid concentrations,
 - CVR releasing estradiol + levonorgestrel, 451
 - ethinylestradiol + levonorgestrel, 451
- Lipids and lipoproteins, effect of CVR releasing estradiol + levonorgestrel, 429
- Lipoprotein patterns, effect of CVR releasing estradiol + levonorgestrel, 469
- Lipoproteins and apolipoproteins,
 - 1effect of CVR releasing estradiol + levonorgestrel, 451
 - effect of ethinylestradiol + levonorgestrel, 451
- Lipoproteins and lipids, effect of CVR releasing estradiol + levonorgestrel, 429
- Lithospermum ruderale plant extract, effect on LHRH activity (chick), 77
- Liver function,
 - CVR releasing estradiol + levonorgestrel, 415
 - effect of medroxyprogesterone acetate, 493
 - ethinylestradiol + levonorgestrel, 415
- Liver function tests,
 - effect of CVR releasing estradiol + levonorgestrel, 415
 - effect of ethinylestradiol + levonorgestrel, 415
- Low density lipoprotein cholesterol (LDL-C), effect of CVR releasing estradiol +

CONTRACEPTION

levonorgestrel, 429, 469

Low density lipoproteins (LDL),

effect of CVR releasing estradiol + levonorgestrel on serum level, 429, 451

effect of ethinylestradiol + levonorgestrel on serum level, 451

Luteinizing hormone (LH),

effect of dimeric ethynodiol-testosterone ester on serum level (rat), 61

effect of ethinyl estradiol + d-norgestrel on serum level, 159

effect of gossypol on pituitary and serum concentrations (hamster), 259

effect of LH-RH antagonist on serum concentration (monkey), 275

effect of LHRH antagonist on serum level, 315

effect of norethindrone enanthate on serum level (rat), 61

relationship to Ovutron readings, 635

Luteinizing hormone releasing hormone (LHRH)

Lutropin (LH), effect of medroxyprogesterone acetate on plasma level, 117, 543

Lynoestrenol, effect on forward migration of spermatozoa, 183

Male antifertility agent,

6-chloro-6-deoxyglucose (rat), 577

dimeric ethynodiol-testosterone ester (rat), 61

gossypol (boar), 569

gossypol (female hamster), 259

gossypol (mouse, rat, hamster), 97

gossypol (rabbit), 203

norethindrone enanthate (rat), 61

Mast cells in uterine fluid, effect of IUD, 685

Medical examination results,

CVR releasing estradiol + levonorgestrel, 359

ethinylestradiol + levonorgestrel, 359

Medications taken,

use of CVR releasing estradiol + levonorgestrel, 359

use of ethinylestradiol + levonorgestrel, 359

Medroxyprogesterone acetate,

assessment on risk-benefit ratio, 493

beagle dog toxicology, 493

commentary on article "Depo-Provera, a critical analysis", 493

effect of dexamethasone suppression and subsequent ACTH stimulation, 543

effect on abortifacient action of Pr- β -hCG-TT antibodies (baboon), 83

effect on adrenal function, 543

- effect on breast-fed infant, 493
- effect on carbohydrate metabolism, 493
- effect on egg transport (rabbit), 107
- effect on endometrium, 493
- effect on forward migration of spermatozoa, 183
- effect on liver function, 493
- effect on milk quality and quantity, 493
- effect on ovarian and adrenal steroids at different phases of menstrual cycle, 117, 543
- effect on progeny, 493
- general damage, 493
- immunosuppressive effects, 493
- informing the medical community, 493
- mode of action, 493
- monkey toxicology, 493
- progesterone and progestogens as carcinogens, 493
- pyometra as precancerous lesion, 493
- toxicological evaluation, 493

Menstrual cycle,

- effect of chronic LHRH agonist treatment (monkey), 647
- effect of LHRH antagonist, 315
- effects of LH-RH antagonist (monkey), 275
- effect of medroxyprogesterone acetate on ovarian and adrenal steroids at different phases, 117, 543

Menstrual diary data,

- CVR releasing estradiol + levonorgestrel, 377
- ethynylestradiol + levonorgestrel, 377

Menstrual patterns,

- effect of CVR releasing estradiol + levonorgestrel, 377
- effect of ethynylestradiol + levonorgestrel, 377

Mentha arvensis plant extract,

- antigonadotropic activity (rat), 559
- estrogenic activity (rat), 559
- uterotonic effect (rat), 559

Mestranol + norethindrone, effect on pituitary response to LHRH stimulation, 229

Metabolic effects,

- CVR releasing estradiol + levonorgestrel, 415, 451

CONTRACEPTION

- ethinylestradiol + levonorgestrel, 415, 451
- Method related factors, contraceptive choice and use, 245
- Methyltestosterone potentiation, gossypol (rat), 97
- Midtrimester abortion, intramuscular injections of Sulprostone, 145
- Migration of spermatozoa, effects of steroids, 183
- Milk quality and quantity, effect of medroxyprogesterone acetate, 493
- Mitotic index in uterine horn, effect of inhibin (mouse), 695
- Mode of action, medroxyprogesterone acetate, 493
- Monkey toxicology, medroxyprogesterone acetate, 493
- Mononuclear phagocytic cells in uterine fluid, effect of IUD, 685
- Most liked characteristic, CVR, 393
- Myometrial activity, influence of copper ions, 195
- NAc-D-p-Cl-Phe^{1,2}, D-Trp³, D-Phe⁶, D-Ala¹⁰-LHRH, anovulatory effect, 315
- (N-Ac-D-Trp^{1,3}, D-p-Cl-Phe², D-Phe⁶, D-Ala¹⁰)-LH-RH, effects during preovulatory period (monkey), 275
- Nelaton catheter vs. laminaria, cervical dilatation, 53
- Nonbleeding intervals,
 - effect of CVR releasing estradiol + levonorgestrel, 377
 - effect of ethinylestradiol + levonorgestrel, 377
- Nonoxynol-9, polyurethane contraceptive vaginal sponge, 235
- Norethindrone, effect on forward migration of spermatozoa, 183
- Norethindrone enanthate, effect on spermatogenesis (rat), 61
- Norethisterone,
 - bioavailability after norethisterone oenanthate, 15
 - pharmacokinetic and pharmacodynamic studies, 29
 - pharmacokinetic parameters for elimination, 15
 - plasma levels following norethisterone-releasing vaginal device, 29
 - serum concentration after norethisterone oenanthate, 15
 - terminal half-life and bioavailability, 673
 - terminal half-life and bioavailability (rat, beagle, monkey), 673
- Norethisterone oenanthate,
 - pharmacokinetic parameters for elimination, 15
 - pharmacokinetics, 15
 - serum concentration after norethisterone oenanthate, 15
- Norethynodrel, effect on forward migration of spermatozoa, 183
- Noregestimate (d-17 β -acetoxy-13 β -ethyl-17 α -ethynyl-4-gonene-3-one oxime)
- Norgestrel, effect on forward migration of spermatozoa, 183

Nova-T,

clinical performance, 529

cumulative rates, 529

Objective and subjective measures of effects,

CVR releasing estradiol + levonorgestrel, 359

ethinylestradiol + levonorgestrel, 359

Obstetric interventions, former use of oral contraceptives, 1

Oestradiol-17 α , effect on forward migration of spermatozoa, 183

Oestradiol-17 β , effect on forward migration of spermatozoa, 183

Oestriol, effect on forward migration of spermatozoa, 183

Oestrone, effect on forward migration of spermatozoa, 183

Oral contraceptive,

complications of pregnancy and labor by former users, 1

effect on relative risk of toxic-shock syndrome, 631

ethinylestradiol + levonorgestrel, 415, 451, 481

ethinylestradiol + lynestrenol, 589

ethinyl estradiol + norethindrone, 229

ethinyl estradiol + norethindrone acetate, 229

ethinyl estradiol + norgestimate, 173

ethinyl estradiol + d-norgestrel, 159, 229, 589

ethinylestradiol + levonorgestrel, 341, 359, 377

mestranol + norethindrone, 229

study of contraceptive choice and use, 245

Oral contraceptives and risk of cancer, access to data and information explosion, 301

Organ weights,

effect of 6-chloro-6-deoxyglucose (rat), 577

effect of gossypol (hamster), 259

Ornithine decarboxylase, effect of α -difluoromethylornithine on level in uterus

(rat), 215

Ovarian and adrenal steroids, different phases of menstrual cycle, 117, 543

Ovarian and pituitary function, effect of ethinyl estradiol + d-norgestrel, 159

Ovarian effects, norethisterone when administered by different route, 29

Ovarian reaction, vaginal device releasing norethisterone, 29

Ovary, effects of chronic LHRH agonist treatment (monkey), 647

Ovulation,

effect of antiserum to FSH (mouse), 695

effect of gossypol (hamster), 259

CONTRACEPTION

- effect of gossypol (mouse, rat), 97
- effect of inhibin (mouse), 695
- Ovulation prediction, use of Ovutron, 635
- Ovutron^R readings and BBT,
 - correlation with sex-hormone and LH levels, 635
 - correlation with size of dominant follicle by ultrasound, 635
- Perception of menstrual pattern changes,
 - CVR releasing estradiol + levonorgestrel, 377
 - ethynylestradiol + levonorgestrel, 377
- PGE₂ (prostaglandin E₂)
- PGF₂ α (prostaglandin (F₂ α))
- Phagocytic activity of mononuclear cells in uterine fluid, effect of IUD, 685
- Pharmacokinetic and pharmacodynamic studies, vaginal device releasing norethisterone, 29
- Pharmacokinetic properties of gestagen,
 - relationship to side effects (rat, dog), 673
 - relationship to toxic effects, 673
- Pharmacokinetics, norethisterone oenanthate, 15
- 16-Phenoxy PGE₂ methyl sulfonylamide (Sulprostone),
 - first trimester abortion with intramuscular injections, 145
 - midtrimester abortion with intramuscular injections, 145
- Pituitary and ovarian function, effect of ethinyl estradiol + d-norgestrel, 159
- Pituitary response, LHRH stimulation during oral contraceptive use, 229
- Platinum or gold core copper-based IUD, in vitro and in vivo studies, 657
- Polyurethane contraceptive vaginal sponge, 235
- Post-coital antifertility agent, α -difluoromethylornithine (rat), 215
- Postcoital antifertility effect, Mentha arvensis plant extract (rat), 559
- Pr- β -hCG-TT, return of fertility (baboon), 83
- Pr- β -hCG-TT antibodies,
 - effect of medroxyprogesterone acetate (baboon), 83
 - effect on terminating pregnancy (baboon), 83
- Pregnancy,
 - effect of gossypol (mouse, rat), 97
 - effect of Mentha arvensis plant extract (rat), 559
 - Nova-T and copper-T-200, 529
- Pregnancy complications, former use of oral contraceptives, 1
- Pregnancy termination,
 - effect of antibodies generated by Pr- β -hCG-TT (baboon), 83

- effect of Win 32,729 (rat, monkey), 289
- Pregnanediol, effect of LHRH antagonist on urinary values, 315
- Pregnenolone, effect of medroxyprogesterone acetate on plasma level, 117, 543
- Preovulatory period, effects of LH-RH antagonist (monkey), 275
- Problems of contraceptive use,
 - CVR releasing estradiol + levonorgestrel, 341
 - ethinylestradiol + levonorgestrel, 341
- Product modification resulting from user experience, polyurethane contraceptive vaginal sponge, 235
- Progeny, effect of medroxyprogesterone acetate, 493
- Progesterone,
 - effect of gossypol on ovarian and serum concentrations (hamster), 259
 - effect of LH-RH antagonist on serum concentration (monkey), 275
 - effect of LHRH antagonist on serum level, 315
 - effect of medroxyprogesterone acetate on plasma level, 117, 543
 - effect of RMI-12,936 on circulating level (rabbit), 107
 - effect of (15S)-15-methyl $\text{PGF}_2\alpha$ methyl ester on serum level, 603, 617
 - effect of Win 32,729 on plasma level (rat), 289
 - effect on forward migration of spermatozoa, 183
 - effect on Win 32,729 action (rat), 289
 - relationship to Ovutron readings, 635
- Progesterone and progestogens as carcinogens, medroxyprogesterone acetate, 493
- Progestogenic effect,
 - dimeric ethynodiol-testosterone ester (rabbit), 61
 - norethindrone enanthate (rabbit), 61
- Prostaglandin analogue,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE_2 , 45, 151
 - 16-phenoxy PGE_2 methyl sulfonylamide, 145
 - (15S)-15-methyl $\text{PGF}_2\alpha$ methyl ester, 603, 617
- Prostaglandin E_2 (PGE_2)
- Prostaglandin $\text{F}_{2\alpha}$ ($\text{PGF}_{2\alpha}$)
- Pyometra as precancerous lesion, medroxyprogesterone acetate, 493
- Quinacrine hydrochloride, toxic effects (monkey), 269
- Reasons for discontinuation,
 - CVR, 393
 - CVR releasing estradiol + levonorgestrel, 451
 - ethinylestradiol + levonorgestrel, 451
- Relative risk of toxic-shock syndrome, effect of contraceptive method, 631

CONTRACEPTION

- Release of estradiol and levonorgestrel from CVRs, 323
- Respiration, effect of gossypol on spermatozoa (boar), 569
- Risk-benefit ratio, medroxyprogesterone acetate, 493
- RMI-12,936 (17β -hydroxy- 7α -methylandrosta-5-en-3-one),
 - effect on fertilization and egg transport (rabbit), 107
 - effect on temporal changes in serum steroids (rabbit), 107
- Route of administration, influence on ovarian effects by norethisterone, 29
- Rural and urban population, acceptability of CVR, 393
- (15S)-15-methyl $\text{PGF}_{2\alpha}$, effect of (15S)-15-methyl $\text{PGF}_{2\alpha}$ methyl ester on serum level, 603
- (15S)-15-methyl $\text{PGF}_{2\alpha}$ methyl ester,
 - abortifacient results, 617
 - bleeding pattern, 603
 - plasma (15S)-15-methyl $\text{PGF}_{2\alpha}$, 603
 - serum β -hCG, 603, 617
 - serum progesterone, 603, 617
 - side effects, 603, 617
 - termination of early gestation, 617
 - termination of very early pregnancy, 603
- Salpingitis, influence of IUD on course of disease, 137
- Second trimester abortion, vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE_2 , 151
- Self-administration of prostaglandin, termination of early pregnancy, 45
- Self-reported side effects,
 - CVR releasing estradiol + levonorgestrel, 359
 - ethinylestradiol + levonorgestrel, 359
- Serum parameters, effect of 6-chloro-6-deoxyglucose (rat), 577
- Service related factors, contraceptive choice and use, 245
- "Shell" ring, improved CVR releasing estradiol + levonorgestrel, 323
- Side effects,
 - CVR releasing estradiol + levonorgestrel, 359
 - 9-deoxo-16,16-dimethyl-9-methylene PGE_2 , 45, 151
 - ethinylestradiol + levonorgestrel, 359
 - intramuscular injections of Sulprostone, 145
 - (15S)-15-methyl $\text{PGF}_{2\alpha}$ methyl ester, 603, 617
- Sperm motility, effect of gossypol (rabbit), 203
- Sperm penetration test, effect of ethinyl estradiol + norgestimate, 173

- Sperm population, effect of gossypol (rabbit), 203
- Spermatocoele production, effect of 6-chloro-6-deoxyglucose (rat), 577
- Spermatogenesis,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of norethindrone enanthate (rat), 61
- Spermatozoal electron transport chain segments, effect of gossypol (boar), 569
- Spermatozoal forward migration, effects of steroids, 183
- Permicide-containing contraceptive, effect on relative risk of toxic-shock syndrome, 631
- Subjective and objective measures of effects,
 - CVR releasing estradiol + levonorgestrel, 359
 - ethynylestradiol + levonorgestrel, 359
- Sulprostone (16-phenoxy PGE₂ methyl sulfonamide)
- TCu 200, effect on cellular composition of uterine fluid, 685
- Terminal half-life,
 - cyproterone acetate, 673
 - cyproterone acetate (rat, beagle, monkey), 673
 - Gestodene, 673
 - Gestodene (rat, beagle, monkey), 673
 - levonorgestrel, 673
 - levonorgestrel (rat, beagle, monkey), 673
 - norethisterone, 673
 - norethisterone (rat, beagle, monkey), 673
- Termination and continuation rates,
 - CVR releasing estradiol + levonorgestrel, 341
 - ethynylestradiol + levonorgestrel, 341
- Termination of early gestation, (15S)-15-methyl PGF_{2α} methyl ester, 617
- Termination of early pregnancy, self-administration of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45
- Termination of pregnancy, effect of Win 32,729 (rat, monkey), 289
- Termination of very early pregnancy, (15S)-15-methyl PGF_{2α} methyl ester, 603
- Terminations of medical reasons,
 - CVR releasing estradiol + levonorgestrel, 341
 - ethynylestradiol + levonorgestrel, 341
- Testicular weight,
 - effect of dimeric ethynodiol-testosterone ester (rat), 61
 - effect of gossypol (rabbit), 203
 - effect of norethindrone enanthate (rat), 61

CONTRACEPTION

Testosterone,

- effect of dimeric ethynodiol-testosterone ester on serum level (rat), 61
- effect of gossypol on serum level (rabbit), 203
- effect of medroxyprogesterone acetate on plasma level, 117, 543
- effect of norethindrone enanthate on serum level (rat), 61
- effect of RMI-12,936 on circulating level (rabbit), 107
- effect on forward migration of spermatozoa, 183

Testosterone enanthate, effect on egg transport (rabbit), 107

Testosterone release in vitro, effect of gossypol (rat), 203

Total immunoreactive estrogen, relationship to Ovutron readings, 635

Toxic effects, quinacrine hydrochloride (monkey), 269

Toxic-shock syndrome and contraception, 631

Toxicity trial, 6-chloro-6-deoxyglucose (rat), 577

Toxicological effects, gossypol (rabbit), 203

Toxicological evaluation, medroxyprogesterone acetate, 493

Triglycerides,

- effect of CVR releasing estradiol + levonorgestrel on serum level, 429, 451, 469
- effect of ethinylestradiol + levonorgestrel on serum level, 451

Urban and rural population, acceptability of CVR, 393

Use effectiveness

- CVR releasing estradiol + levonorgestrel, 341
- ethinylestradiol + levonorgestrel, 341

Use of chosen contraceptive method, Bangkok Metropolis Health Clinics, 245

Use-related terminations,

- CVR releasing estradiol + levonorgestrel, 341
- ethinylestradiol + levonorgestrel, 341

User experience resulting in product modifications, polyurethane contraceptive vaginal sponge, 235

Uterine activity,

- effect of intrauterine instillation of CuCl_2 , 195
- influence of copper ions (rabbit), 195

Uterine fluid, cellular composition in IUD users, 685

Uterine response, effect of Mentha arvensis plant extract (rat), 559

Uterotonic effect, Mentha arvensis plant extract (rat), 559

Uterus, effects of chronic LHRH agonist treatment (monkey), 647

Vaginal contraceptive sponge, product modification resulting from user experience, 235


CONTRACEPTION

- Vaginal cytology, effect of ethinyl estradiol + norgestimate, 173
- Vaginal device releasing norethisterone, pharmacokinetic and pharmacodynamic studies, 29
- Vaginal flora,
 - effect of CVR releasing estradiol + levonorgestrel, 481
 - effect of ethinyl estradiol + levonorgestrel, 481
- Vaginal suppository,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 45, 151
 - (15S)-15-methyl PGF_{2α} methyl ester, 603, 617
- Very early pregnancy termination, (15S)-15-methyl PGF_{2α} methyl ester, 603
- Very low density lipoproteins (VLDL),
 - effect of CVR releasing estradiol + levonorgestrel on serum level, 429, 451
 - effect of ethinylestradiol + levonorgestrel on serum level, 451
- Weight changes,
 - CVR releasing estradiol + levonorgestrel, 359
 - ethinylestradiol + levonorgestrel, 359
- Win 32,729 ((2α, 4α, 5α, 17β)-4,5-epoxy-17-hydroxy-4,17-dimethyl-3-oxoandrostane-2-carbonitrile), interceptive agent (rat, monkey), 289

Vol. 24 1981
July - December
ISSN 0010-7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M.D.—Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

EDITOR

Daniel R. Mishell, Jr., M.D.
Dept. of Obstetrics and Gynecology
University of Southern California School of Medicine
1240 North Mission Road
Los Angeles, California 90033

EDITORIAL ASSISTANTS

Alberta Lawson
Janis H. Torres

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

C. Wayne Bardin, M.D.
Director, Center for Biomedical
Research
The Population Council
1230 York Avenue
New York, New York 10021

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Uwe Goebelsmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduc-
tion & Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.
Professor and Chairman
Department of Medicine
University of Utah College of
Medicine
Salt Lake City, Utah 84132

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior Street
Chicago, Illinois 60611

Sheldon Segal, Ph.D.
Director,
Population Division
Rockefeller Foundation
1133 Avenue of the Americas
New York, New York 10036

William N. Spellacy, M.D.
Professor and Head
Department of Obstetrics
and Gynecology
The Abraham Lincoln
School of Medicine
University of Illinois
Medical Center
840 South Wood Street
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.
Associate Director
Center for Biomedical Research
Rockefeller University
York Avenue & 66th Street
New York, N.Y. 10021

Corresponding Editors for CONTRACEPTION

E. Coutinho, M.D.
Professor
Department of Biochemistry
and Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL

P. G. Crosignani, M.D.
Professor
IV Department of Obstetrics
and Gynecology
University of Milano
Via M. Mellon, 52
20429 Milano, ITALY

E. Diczfalusy, M.D.
Professor
Reprod. Endocrinology
Research Unit
Swedish Med. Research Council
Karolinska Sjukhuset
Stockholm 60, SWEDEN

J. Ferin, M.D.
Professor
Physiology of Human Reprod.
Research Unit
University of Louvain Hosp.
Louvain, BELGIUM

C. Gual, M.D.
Instituto Nacional de la Nutricion
Hospital de Enfermedades de la
Nutricion
Av. San Fernando y
Viaducto Tlalpan
Mexico 22, D.F., MEXICO

I. Hallbrecht, M.D.
Professor
Department of Obstetrics
and Gynecology
Tel Aviv University Med. School
Tel Aviv, ISRAEL

J. Hammerstein, M.D.
Professor
Abt. Gynaek. Endokrinologie
Sterilitat und Familienplanung
Freie Universitat Berlin
Hindenburgdamm 30
1000 Berlin 45
FED. REP. GERMANY

A. A. Haspels, M.D., Prof.
Department of Obstetrics
and Gynecology
Academic Hospital
University of Utrecht
Catharjnesingel 101
Utrecht, NETHERLANDS

T. Luukkainen, M.D.
Steriod Research Laboratory
University of Helsinki
Department of Med. Chemistry
Siltavuorenpenger 10A
SF-00170 Helsinki 17,
FINLAND

J. R. Newton, M.D., Prof.
Birmingham Maternity Hospital
Queen Elizabeth Medical Centre
Edgbaston, Birmingham 15
ENGLAND

Badri N. Saxena, M.D.
Deputy Director General
Indian Council of
Medical Research
Ansari Nagar
New Delhi-110016, INDIA

R. P. Shearman, M.D.
Professor of Obstetrics
and Gynecology
The University of Sydney
Sydney 2006, N.S.W.
AUSTRALIA

M. Vessey, M.D.
Professor, University Dept. of
Social & Community Med.
University of Oxford
8 Keble Road
Oxford, OX13QN
ENGLAND

J. Zanartu, M.D.
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clinica
Obstetrica
Hospital Jose Joaquin Aguirre
Casilla 6637
Santiago, CHILE

Complications of Pregnancy and Labor in Former Oral Contraceptive Users S. Harlap, A.M. Davies and M. Baras.....	1
Pharmacokinetics of Norethisterone Oenanthate in Humans G.W. Sang, K. Fotherby, G. Howard, M. Elder and P.G. Bye.....	15
Pharmacokinetic and Pharmacodynamic Studies with Vaginal Devices Releasing Norethisterone at a Constant, Near Zero Order B.-M. Landgren, M.A. Oriowo and E. Diezfallusy.....	29
Self-Administration of Prostaglandin for Termination of Early Pregnancy M. Bygdeman, N.J. Christensen, K. Gr��en and S. Zheng.....	45
Nelaton Catheter Versus Laminaria for a Safe and Gradual Cervical Dilatation Y. Manabe and A. Manabe.....	53
Reversible Inhibition of Spermatogenesis by a Long-Acting Dimeric Ethynodiol-Testosterone Ester H. Kuhl, I. Franz, H.-J. Born, M. Schneider and H.-D. Taubert.....	61
The <u>In-Vivo</u> Effect of <u>Lithospermum Ruderale</u> on LHRH Activity in the Chick F.J. Zeller and W.R. Breneman.....	77
Efficacy of Antibodies Generated by Pr-��-hCG-TT to Terminate Pregnancy in Baboons: Its Reversibility and Rescue by Medroxyprogesterone Acetate A. Tandon, C. Das, B.L. Jalkhani and G.P. Talwar.....	83
Antifertility and Endocrine Activities of Gossypol in Rodents D.W. Hahn, C. Rusticus, A. Probst, R. Homm and A.N. Johnson.....	97
Effect of RMI-12,936 on Fertilization and Egg Transport in the Rabbit S.K. Saksena, I.F. Lau and R. Salmonsens.....	107

  1981, Geron-X, Inc.

CONTRACEPTION is published monthly by Geron-X, Inc.,
Box 1108, Los Altos, California 94022, USA
(415) 493-0871

Two volumes per year

Personal subscription \$ 70 per year

Institutional subscription \$110 per year

Add \$10 for surface postage outside USA

Add \$24 for airmail USA. Add \$40 for airmail outside USA

Second-class postage paid at Los Altos, Calif. and at additional mailing office.

CONTRACEPTION

August 1981

Volume 24, Number 2

Studies on Ovarian and Adrenal Steroids at Different Phases of the Menstrual Cycle. III. Steroid and Lutropin Levels Before and After the Administration of a Single Contraceptive Dose of Depot-Medroxyprogesterone Acetate (DMPA) A.-R. Aedo, B.-M. Landgren and E. Diezfalusy.....	117
Influence of an Intrauterine Device on the Course of an Acute Salpingitis G. Söderberg and S. Lindgren.....	137
First and Midtrimester Abortion with Intramuscular Injections of Sulprostone C.A. Ballard.....	145
The Vaginal Administration of 9-deoxo-16,16-dimethyl-9-methylene PGE ₂ for Second Trimester Abortion C.A. Ballard.....	151
Further Studies on Pituitary and Ovarian Function in Women Receiving Hormonal Contraception B.L. Cohen and M. Katz.....	159
Effects of Norgestimate in Combination with Ethinyl Estradiol on Cervical Mucus M. Mohsenian, K.S. Moghissi and K. Borin.....	173
Effects of Steroids on the <u>In Vitro</u> Forward Migration of Human Spermatozoa C.Y. Cheng and B. Boettcher.....	183
Influence of Copper Ions on Uterine Activity T. Ludański, E. Kobylec and M. Åkerlund.....	195
Gossypol: Its Toxicological and Endocrinological Effects in Male Rabbits S.K. Saksena, R. Salmonsén, I.F. Lau and M.C. Chang.....	203
α -Difluoromethylornithine As a Postcoitally Effective Antifertility Agent in Female Rats P.R.K. Reddy and V. Rukmini.....	215
Letters to Editor.....	223
Announcement.....	227

CONTRACEPTION

September, 1981

Volume 24, Number 3

Pituitary Response to LHRH Stimulation in Women on Oral Contraceptives: A Followup Dose Response Study L.S. Wan, M. Ganguly and G. Weiss,.....	229
Polyurethane Contraceptive Vaginal Sponge: Product Modifications Resulting from User Experience R. Aznar, G. Zamora, M. Lozano and C. Levi.....	235
A Study of Contraceptive Choice and Use in Bangkok Metropolis Health Clinics T. Chumnijarakij, R.A. Grossman, Y. Onthum, S. Muttamara and P. Charumilind.....	245
Effects of Gossypol on Pituitary-Ovarian Endocrine Function, Ovulation and Fertility in Female Hamsters Y.-M. Wu, S.C. Chappel and G.L. Flickinger.....	259
Toxic Effects of Quinaerine Hydrochloride in Rhesus Monkeys H. Chandra and B. Malaviya.....	269
The Effects of an LH-RH Antagonist ([N-Ac-D-Trp ^{1,3} ,D-p-CI-Phe ² ,D-Phe ⁶ ,D-Ala ¹⁰]-LH-RH) During the Preovulatory Period of the Rhesus Monkey J.P. Balmaceda, A.V. Schally, D. Coy and R.H. Asch.....	275
Effect of Intrauterine Administration of Antiprostaglandin Drugs on Implantation in the Rat U. Gupta, N. Malhotra, S.K. Varma and R.R. Chaudhury.....	283
WIN 32,729, a New, Potent Interceptive Agent in Rats and Rhesus Monkeys J.E. Creange, A.J. Anzalone, G.O. Potts and H.P. Schane.....	289
Access to Data and the Information Explosion: Oral Contraceptives and Risk of Cancer J.M. Weiner, S. Shirley, N.J. Gilman, S.M. Stowe and R.M. Wolf.....	301
Anovulatory Effect of a LHRH Antagonist in Women A. Zarate, E.S. Canales, I. Sthory, D.H. Coy, A. M. Comaru-Schally and A.V. Schally.....	315

CONTRACEPTION

October 1981

Volume 24, Number 4

Editorial Comment	
C.W. Bardin.....	321
Levonorgestrel and Estradiol Release from an Improved Contraceptive Vaginal Ring	
T.M. Jackanicz.....	323
A Multicenter Study of Levonorgestrel-Estradiol Contraceptive Vaginal Rings. I. Use Effectiveness	
An International Comparative Trial.....	341
A Multicenter Study of Levonorgestrel-Estradiol Contraceptive Vaginal Rings. II. Subjective and Objective Measures of Effects	
An International Comparative Trial.....	359
A Multicenter Study of Levonorgestrel-Estradiol Contraceptive Vaginal Rings. III. Menstrual Patterns	
An International Comparative Trial.....	377
Acceptability of the Contraceptive Vaginal Ring By Rural and Urban Population in Two Latin American Countries	
A. Faundes, E. Hardy, Q. Reyes, L. Pastene and R. Portes-Carrasco.....	393
Comparison of the Metabolic Effects of Two Hormonal Contraceptive Methods: An Oral Formulation and a Vaginal Ring.	
I. Carbohydrate Metabolism and Liver Function	
T. Åhrén, A. Victor, H. Lithell and E.D.B. Johansson.....	415
The Effect on Lipids and Lipoproteins of a Contraceptive Vaginal Ring Containing Levonorgestrel and Estradiol	
S. Roy, R.M. Krauss, D.R. Mishell, Jr., J. Casagrande and M.C. Pike.....	429
Comparison of the Metabolic Effects of Two Hormonal Contraceptive Methods: An Oral Formulation and a Vaginal Ring. II. Serum Lipoproteins and Apolipoproteins	
T. Åhrén, H. Lithell, A. Victor, B. Vessby and E.D.B. Johansson.....	451
Lipoprotein Patterns in Women in Santo Domingo Using a Levonorgestrel/Estradiol Contraceptive Ring	
D.N. Robertson, F. Alvarez, I. Sivin, V. Brache, J. Stern, P. Leon and A. Faundes.....	469
The Effect of a Contraceptive Vaginal Ring and Oral Contraceptives on the Vaginal Flora	
S. Roy, J. Wilkins and D.R. Mishell, Jr.....	481

CONTRACEPTION

November 1981

Volume 24, Number 5

The Depo-Provera Debate. Commentary on the Article "Depo-Provera, A Critical Analysis" G. Benagiano and I. Fraser.....	493
Intrauterine Contraception with Nova-T and Copper-T-200 During Three Years K.-G. Nygren, N.-C. Nielsen, T. Pyörälä, H. Allonen., and T. Luukkainen.....	529
Studies on Ovarian and Adrenal Steroids at Different Phases of the Menstrual Cycle. IV. The Effect of Dexamethasone Suppression and Subsequent ACTH Stimulation at Different Phases of the Menstrual Cycle and Following the Administration of 150 mg of Depot-Medroxyprogesterone Acetate (DMPA) A.-R. Aedo, B.-M. Landgren and E. Diezfalussy.....	543
Postcoital Antifertility Effect of <i>Mentha arvensis</i> D. Kanjanapothi, Y. Smitasiri, A. Panthong, T. Taesotikul and V. Rattanapanone.....	559
Variations of Gossypol Sensitivity in Boar Spermatozoal Electron Transport Chain Segments W.-W. Tso and C.-S. Lee.....	569
The Effect of High Doses of 6-Chloro-6-Deoxyglucose on the Rat W.C.L. Ford and G.M.H. Waite.....	577
Plasma Levels of Ethinylestradiol (EE) During Cyclic Treatment with Combined Oral Contraceptives J.M. Kaufman, M. Thiery and A. Vermeulen.....	589

CONTRACEPTION

December 1981

Volume 24, Number 6

Termination of Very Early Pregnancy by Vaginal Suppositories — (15S)-15-Methyl Prostaglandin F _{2α} Methyl Ester L.S. Wan, A.J. Stiber and J. Turkel.....	603
Termination of Early Gestation with (15S)-15-Methyl-Prostaglandin F _{2α} Methyl Ester Vaginal Suppositories R.P. Marrs, P.F. Brenner, S. Roy and D.R. Mishell, Jr.....	617
Contraception and Toxic-Shock Syndrome: A Reanalysis J.D. Shelton and J.E. Higgins.....	631
Correlation of Ovutron Readings and the Basal Body Temperature (BBT) with Serum Sex-Hormone and Luteinizing Hormone Levels S. Roy and D.R. Mishell, Jr.....	635
Effects of Chronic LHRH Agonist Treatment on the Endometrium and Ovaries of the Stumptailed Macaque R.H.J. Kerr-Wilson, L. MacKenzie and H.M. Fraser.....	647
A Copper-Based Intrauterine Device with Gold or Platinum Core: In Vitro and In Vivo Studies R. Gonen, L. Gal-Or, A. Zilberman and M. Scharf.....	657
Terminal Half-Lives in Plasma and Bioavailability of Norethisterone, Levonorgestrel, Cyproterone Acetate and Gestodene in Rats, Beagles and Rhesus Monkeys B. Düsterberg, M. Humpel and U. Speck.....	673
The Cellular Composition of Uterine Fluid in IUD Users — A Quantitative Study B. Casslén, T.K. Kobayashi and N. Stormby.....	685
Effect of Inhibin on Ovulation and Implantation in Mice T.D. Nandedkar, S. Vijayalashmi, B.S. Sarvamangala, S.B. Moodbidri, S.R. Munshi and A.R. Sheth.....	695
Announcement.....	705
Author Index for Volume 24.....	707
Subject Index for Volume 24.....	711

